The Primate Ficolins by Nissen, Janna
The Primate ficolins 
 
 
 
 
 
Master’s Thesis in Biomedicine 
University of Roskilde and  
Tissue Typing Laboratory, 
Rigshospitalet 
 
May 2010 
Janna Nissen 
 Preface 
This Master’s Thesis was carried out from June 2009 to May 2010. The experimental work was 
conducted at the Laboratory of Molecular Medicine, Department of Clinical Immunology section 
7631 at Copenhagen University Hospital (Rigshospitalet), Denmark, under the supervision of 
Professor Peter Garred. Associate professor Claus Koch and associate professor Cathy Mitchelmore 
have been internal supervisors on the project. 
 
During my Master thesis I attended the conference: 12
th
 European Meeting on Complement in 
Human Disease (CHD 2009), Visegrad, Hungary, where I was given the opportunity to present my 
work with an oral presentation about “Characterization of the ficolin genes (FCNs) in primates” 
(appendix 9.4). 
 
On the 6
th
 of May 2010 I am going to attend the annual meting hold by the Association of younger 
scientists (FYF) at the Copenhagen University Hospital. I will represent my work with a poster- 
presentation (appendix 9.5). 
Acknowledgements 
I would like to express my gratitude to everyone who has helped me during this project. First of all 
I would like to thank Professor Peter Garred for giving me the opportunity to carry out my Master’s 
Thesis in his laboratory and for his interest in my project. Also, I would like to thank him for letting 
me participate in the CHD 2009 Conference in Hungary, which has been a great and valuable 
experience. 
  
I would like to thank my colleagues at the PG-group for a stimulating and pleasant atmosphere in 
the laboratory. Particularly, I would like to thank MD, PhD Tina Hummelshøj, MSc, PhD-student 
Lea Munthe-Fog for daily supervision, technical support and guidance. A special thank to MD, PhD 
Ying Jie Ma for sharing his expertise with me. 
 
I thank my supervisors associate professor Claus Koch and associate professor Cathy Michelmore 
for pleasant collaboration. Finally, I thank Staff Veterinarian Mads Berthelsen from Centre for Zoo 
and Wild Animal Health, Copenhagen Zoo, for providing primate sera. 
 
Copenhagen, May 2010  
 
Janna Nissen 
 Summary 
Ficolins are pattern recognition molecules that share structural similarities with mannose-binding 
lectin (MBL), whose key function is to recognize carbohydrates on microorganisms or epitopes on 
dying host cells and subsequently are capable of activating the complement system, through the 
lectin pathway. In humans, three ficolin genes have been identified; FCN1, FCN2 and FCN3, which 
encode Ficolin-1, Ficolin-2 and Ficolin-3, respectively. Apart from human, ficolins have been 
identified in mice, rats, chickens, pigs, hedgehogs, frogs and ascidians. However, rodents and pigs 
only produce two ficolins designated Ficolin-A (or -!) and Ficolin-B (or -"), which are closely 
related to the human FCN1 and FCN2 genes. Nevertheless, in mice a pseudogene corresponding to 
the human FCN3 gene has also been identified. Currently, Ficolin-3 has only been purified and 
characterized in human. Thus, we aimed to identify and characterize the FCN1, FCN2 and FCN3 in 
primates. We found that the exon organisation is very similar between all the primates included in 
this study and humans. Several novel inter-individual variations were found in all three FCN genes 
within each species. These results indicate that all the investigated primates have functional FCN1, 
FCN2 and FCN3 genes that are closely related to the human FCN1, FCN2 and FCN3 genes, 
respectively. Moreover, two polymorphisms (FCN1: Arg93Gln, FCN2: Ala185Thr) previously 
described in human were found in the chimpanzee and rhesus macaque, respectively. These 
findings indicate that the FCN genes may thus have an ancient origin. Furthermore, we showed that 
higher and lower primates express Ficolin-2 and Ficolin-3 in serum that has the characteristic 
oligomeric structures as seen in humans. This is the first time Ficolin-3 is shown outside the human 
situation. Serum levels of Ficolin-2 and Ficolin-3 were measured in chimpanzees and Ficolin-2 was 
found to be expressed in similar concentrations as found in humans. By contrast, serum Ficolin-3 
was expressed in low concentrations compared to human. Finally, we showed that chimpanzee 
serum contains all the complement components needed to activate and generate MAC formation of 
the classical, the MBL and the alternative pathway of the complement system.   
 
In the human FCN genes 22 non-synonymous SNPs have been described, which were made 
recombinant in CHO cells and subsequently the expression level and the oligomeric structure were 
analysed. The variants rF1W279stop, rF2A264fs and rF3L117fs were not expressed. Normal 
oligomeric structures were observed for the rest of the variants. Binding studies revealed that the 
Ficolin-3 variants E166D and V287A showed a gain-of-function and a loss-of-function towards 
acetylated BSA, respectively, compared to the wild-type. 
 Resumé (Danish) 
Ficoliner er genkendelses-molekyler som deler strukturelle ligheder med mannose-bindende lectiner 
(MBL), hvis primære funktion er at genkende epitoper på overfladen af bakterier og døende vært- 
celler, hvorved de er i stand til at aktivere komplement systemet via lectin aktiveringsvejen. Hos 
mennesket er der beskrevet tre ficolin gener; FCN1, FCN2 og FCN3 som henholdsvis koder for 
Ficolin-1, Ficolin-2 og Ficolin-3. Foruden den menneskelige situation er ficoliner blevet fundet hos 
mus, rotter, kyllinger, grise, pindsvin, frøer og søtunger. Gravere og grise danner kun to ficoliner 
kaldet Ficolin-A (eller -!) og Ficolin-B (eller -"), som er tæt beslægtet med de menneskelige FCN1 
og FCN2 gener. Ikke desto mindre er der hos mus identificeret et pseudogen som svarer til det 
menneskelige FCN3 gen. Indtil videre er Ficolin-3 kun blevet fundet og karakteriseret hos 
mennesket. Vi var derfor interesseret i at identificerer og karakterisere FCN1, FCN2 og FCN3 
generne hos primater. Vi fandt at exon fordelingen var meget ens mellem de undersøgte primater og 
mennesket. Adskillige nye intra-individuelle variationer blev fundet i alle tre FCN gener indenfor 
hver primat. Disse resultater indikerer at de undersøgte primater har funktionelle FCN1, FCN2 og 
FCN3 gener som er tæt beslægtet med de respektive menneskelige FCN1, FCN2 og FCN3 gener. 
Desuden blev to polymorfier (FCN1: Arg93Gln, FCN2: Ala185Thr) som tidligere er beskrevet for 
den menneskelige situation også fundet i henholdsvis chimpanser og rhesusaber. Disse fund 
indikere at FCN generne må have en forhistorisk oprindelse. Endvidere påviste vi at højere og 
lavere stående primater udtrykker Ficolin-2 og Ficolin-3 i serum hvis oligomerings mønster svarer 
til den som ses hos mennesket. Dette er første gang Ficolin-3 er blevet påvist udenfor den 
menneskelige situation. Ficolin-2 og Ficolin-3 serum koncentrationen blev målt i chimpanser og 
Ficolin-2 koncentrationen blev udtrykt i samme grad som hos mennesket. I modsætning var Ficolin-
3 koncentration meget lavere end for den menneskelige situation. Til sidst påviste vi at serum fra 
chimpanser indeholder alle de komplement komponenter der skal til for at aktivere og danne et 
MAC via den klassiske, MBL og den alternative aktiveringsvej af komplement systemet. 
 
I de menneskelige FCN gener er der beskrevet 22 substitution SNPs og disse proteiner blev udtrykt 
in CHO celler og derefter blev deres koncentration og oligomeriserings mønstre analyseret. 
Varianterne rF1W279stop, rF2A264fs og rF3L117fs blev ikke udtrykt. Et normalt oligomerings 
mønstre blev observeret hos resten af varianterne. Et bindingsstudie af Ficolin-3 varianterne E166D 
og V278A blev der henholdsvis fundet en stærkere og en svagere binding mod acetylated BSA i 
forhold til vildtypen.  
 Abbreviations 
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1. Introduction 
Immunity refers to the general ability of a host to resist a particular infection or disease. Immediate 
defence and resistance against potential pathogens are crucial for host survival. The immune system 
can be divided into two categories: the innate and the adaptive immune system. The former 
immune response is mounted rapidly, within seconds and thus represents the first line of host 
defence against potentially invading microorganisms before the adaptive immune system after a 
latency period initiates a response based on effector T-lymphocytes and/or antibodies. Multiple 
connections exist between the innate immune system and the adaptive immune system components. 
This thesis focuses on the innate immune system. 
 
1.1 The innate immune system 
The innate immune system is present at birth and changes little throughout life. It works rapidly 
using different effector mechanisms such as direct phagocytosis, facilitation of phagocytosis 
(opsonization) and creation of an inflammatory response. Activation of the complement system is 
involved in several aspects: opsonization, inflammation and direct killing of microorganisms, and 
also activation of B-lymphocytes and removal of immune complexes. These mechanisms are 
believed to either directly kill the microorganism or to limit the spread and severity of an infection, 
and to modulate the adaptive immune response towards a threatening microorganism [1]. 
 
The innate immune system has specificity for molecular structures on microorganisms and is 
capable of discriminating between self and non-self. The specificity is exercised through Pattern 
Recognition Receptors (PRR), which recognize conserved Pathogen-Associated Molecular Patterns 
(PAMPs) present on the surface of microorganisms or intracellularly. PAMPs, which are essential 
for microorganism survival, are highly conserved structures present in a large group of 
microorganism. Some of the best known examples are lipopolysaccharides (present on gram-
negative cell-walls), peptidoglycan (present on both gram-negative and gram-positive bacteria) 
lipoteichoic acid (present on gram-positive bacteria) and intracellular receptors for bacterial and 
viral DNA [1].  
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1.1.2 Pattern recognition receptors 
Innate immune system combats invading microorganisms, by employing a large group of different 
PRRs. They are all germline-encoded and can be divided into cell-associated receptors or soluble 
molecules [2]. Innate immune responses have no memory and repeated exposure to the same 
microorganisms does not amplify the response in contrast to the adaptive immune response. 
 
The large family of transmembrane Toll-like receptors belong to the group of cell-associated 
receptors. They play a major role as microorganism-sensing receptors and they release cytokines in 
response to binding of microorganisms. Another type of cell-bound receptors is found on 
phagocytic cells, such as the macrophages, which engulf the microorganisms after binding [3]. 
 
Soluble PRRs circulate in the blood and lymph. These PRRs capture microorganisms and act as 
opsonins tagging the microorganisms for phagocytosis. Some soluble PRRs have the ability to 
activate the complement system [3]. Mammalian lectins are PRRs that are defined as carbohydrate-
recognizing proteins that bind to a unique carbohydrate moiety on microorganisms. Lectins can be 
further divided into collectins and ficolins [2]. 
 
Collectins belongs to the superfamily of Ca
2+
-dependent lectins (C-type lectins) and are 
characterized by the presence of the C-type Carbohydrate Recognition Domain (CRD). The lectin 
activity is located in the CRD and show selective binding to mannose, glucose, L-fucose, N-acetyl-
mannosamine (ManNAc) and N-acetyl-glucosamine (GlcNAc) [4, 5]. The best-studied members of 
the collectin family are the serum protein Mannose-Binding Lectin (MBL) and the lung Surfactant 
Protein A (SP-A) and lung Surfactant Protein D (SP-D) [1, 2].  
 
The newly discovered ficolins resemble the collectins particulary MBL regarding the structure and 
function. However, ficolins do not contain a CRD domain; the lectin activity is located in the 
fibrinogen-like domain (FBG) [2, 4]. MBL and the ficolins are soluble lectins that bind surface 
structures on invading microorganisms and are able to activate the lectin pathway of the 
complement system through attached MBL-associated serine proteases (MASPs) in their collagen-
like domain (figure 3). 
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1.2.0 The complement system 
The complement system is an important part of the innate immune system and consists of 
enzymatic cascade reactions involving more than 30 plasma proteins. The complement cascade is 
activated through a down-stream amplification cascade, where the formation of convertase 
complexes gives rise to a powerful response, despite modest initial stimuli. Activation of the 
complement system promotes three main biological activities: opsonization of the microorganisms, 
chemotaxis and activation of leukocytes, and direct killing of the microorganisms. Accumulating 
evidence suggest that the complement system also plays a role as an adjuvant, enhancing and 
directing the adaptive immune response and promoting the elimination of apoptotic cells [6]. 
 
Three distinct pathways can activate the complement system: 1) the classical pathway, 2) the lectin 
pathway and 3) the alternative pathway. All three activation pathways lead to the generation of the 
active C3-convertase, which cleaves C3 into C3a, a local mediator of inflammation, and C3b, 
which is the main effector molecule of the complement system. Deposition of C3b on the surface of 
microorganisms acts as an opsonin, tagging the microorganisms for phagocytosis. Spontaneous 
hydrolysis of C3 converts native C3 into an active C3b like molecule called C3b(H2O). This form 
can be the basis for further C3-convertase (C3(H2O)Bb) formation and subsequently additional C3 
is cleave to C3b, thus resulting in activation through an amplification loop. Finally, C3b binds to 
the C3-convertase and forms a C5-convertase, which cleaves C5 into C5a, an important mediator of 
inflammation, and C5b, which activates a cascade reaction that leads to the assembly of the late 
complement factors C6-C9. This assembly leads to the formation of a Membrane Attack Complex 
(MAC), which forms a pore through the microorganisms membrane making it leaky. As a result, 
water and salts pass through the pore interrupting the intracellular homeostasis, and causing lysis of 
the cell (figure 1)[7].  
 
The anaphylatoxins C3a, C4a and C5a are potent proinflammatory molecules generated from 
cleavage of the complement factors C3, C4 (generated through the activation of the classical and/or 
lectin pathway of complement) and C5, respectively, with C5a being considerably more potent than 
C3a and C4a. Their proinflammatory activities include release of histamine from mast cells and 
basophils causing vascular dilatation and increased permeability, smooth muscle contraction, and 
chemotactic attraction of phagocytes [8, 9]. 
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Figure 1: The classical, lectin and alternative complement pathways and their effector mechanisms [7].  
1.2.1 The classical pathway 
The recognition protein C1q, whose tertiary structure resembles the structure of MBL and the 
ficolins, activates the classical pathway. C1q can bind directly to the surfaces of microorganisms or 
to the Fc-part of immune complexes (IgG og IgM) bound to microorganisms, thus linking the 
effector mechanisms of innate and adaptive immunity (figure 2). Together with C1q, serine 
proteases C1r and C1s form the C1-complex. When Clq is activated it undergoes a conformational 
change, which enables Clr to become self-activated and subsequently cleave and activate C1s. 
Activated C1s proteases cleave C4 and C2 to generate C4b and C2a, which together form the C3-
convertase (C4b2a) (figure 2) [7, 8]. 
1.2.2 The lectin pathway 
There are four recognition molecules, which in association with MASPs can activate the lectin 
pathway of complement: MBL, Ficolin-1, Ficolin-2 and Ficolin-3. When MBL or the ficolins 
recognize and bind PAMPs on the surface of microorganisms, the attached MASPs are activated 
[10]. Five different MASPs have been found; the serine proteases MASP-1, MASP-2, MASP-3 and 
a non-enzymatic protein called small MBL-associated protein (sMAP), a splice variant of MASP-2 
[11]. Recently, the fifth MASPs named MAP-1, which is derived from the MASP1 gene, has been 
found in association with MBL, Ficolin-2 and Ficolin-3 [12]. MASP-2 is capable of cleaving C4 
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and C2, generating C4b and C2a, leading to the formation of a C3-convertase (C4b2a). MASP-1 
may cleave C3 directly (figure 2) [5, 13]. 
1.2.3 The alternative pathway 
The alternative pathway employs a different strategy of complement activation than the classical 
and the lectin pathway. It relies on the unstable nature of the C3 molecule and not on a multivalent 
recognition molecule. C3 is abundant in plasma and spontaneous hydrolysis of the thioester of C3 
results in a C3b analogue, C3(H2O) (figure 2). This activated form binds factor B, and the latter is 
cleaved by factor D into Ba and the fluid-phase C3-convertase C3(H2O)Bb. The fluid-phase C3-
convertase ensures that small amounts of C3b always are available to be deposited on the surface of 
microorganisms, thus initiating the alternative pathway. Factor B binds to the surface C3b and the 
complex undergoes proteolytic cleavage by factor D to form the C3-convertase C3bBb. Recently, it 
has been shown that pro-complement factor D (pro-Df) is cleaved by MASP-1 to generate the 
active complement factor D (Df) [14]. Properdin stabilizes the C3-convertase, which cleaves 
additional C3 into C3b, establishing the C3 amplification loop of the alternative pathway and 
activating the remainder of the cascade [9]. 
 
Figure 2: Activation of the classical, the lectin and the alternative pathways of complement [6].  
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1.2.4 Complement regulation 
The activating mechanisms of complement system are tightly regulated to prevent host cell 
damage. Complement is regulated by actions of fluid-phase and cell-bound inhibitors and 
inactivators. Each step in the complement activation cascade has a regulative mechanism. 
Regulators operate at different levels: 1) C1-inhibitor (C1-inh) acts by inhibiting the enzymatic 
action of C1r and C1s of the classical pathway 2) C3b and C4b deposited on host cells are degraded 
by proteolytic cleavage by factor I. To prevent non-specific degradation, in the case of proper 
complement activation, factor I requires cofactors for its proteolytic activity. A number of 
complement proteins can function as cofactor for factor I for instance factor H and membrane 
cofactor protein (MCP, CD46). 3) If C3b and C4b deposition has lead to the assembly and 
formation of the C3-convertase and/or the C5-convertase, they can be disassembled by regulators 
that have decay-accelerating activity such as decay-accelerating factor (DAF, CD55), complement 
receptor 1 (CR1, CD35) and factor H. 3) The assembly of the MAC formation can be inhibited by 
CD59 and S protein. 5) The activity of the anaphylatoxins (C3a, C4a, C5a) is limited by cleavage 
of terminal arginine with carboxypeptidases. This limits their ability to interact with their respective 
receptors. Deficiency in any of the regulatory mechanisms results in excessive complement 
consumption, which induce an inflammatory response and thereby may damage or destruct host 
cells and tissue [7, 8]. 
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2.The human ficolins 
Ficolins are pattern recognition molecules. Their key function is to recognize carbohydrates and 
acetylated compounds on the surface of microorganism and dying host cells. This enables 
activation of the lectin complement pathway by serine proteases and enhancement of phagocytosis. 
The ficolins were originally identified as transforming growth factor (TGF)-!1-binding proteins on 
porcine uterus membranes [6]. However, this interaction of porcine ficolins with TGF-!1 has not 
been further investigated. The isolated protein contained a FBG domain and a collagen-like 
domain, and contraction of the two words gave rise to the name ficolin (fibrinogen and collagen-
like lectin).  
 
Today, three different human ficolins have been identified and characterized: Ficolin-1 (also called 
M-ficolin/P35 related protein), Ficolin-2 (also called L-ficolin, hucolin, EBP-37, or ficolin/P35) 
and Ficolin-3 (also called H-ficolin, Hakata antigen, thermolabile !-2 macroglycoprotein, or 
thernolabile substance) [10]. Ficolin-2 and Ficolin-3 are serum proteins, whereas Ficolin-1 is a 
membrane-associated protein expressed by monocytes and granulocytes [15]. However, it has 
recently been shown that Ficolin-1 is also present in serum, but in a very low concentration [16].  
 
Besides in human, ficolins have also been identified in other vertebrates such as mice, rats, 
chickens, pigs, hedgehogs, frogs and in the invertebrate ascidian [6]. Rodents and pigs express only 
two ficolins designated Ficolin-A (or ") and Ficolin-B (or !). Ficolin-B is considered to be 
analogous to human Ficolin-1, whereas Ficolin-A corresponds to human Ficolin-2. In mice the 
FCN3 gene is found as a pseudogene containing several stop codons [17]. There is evidence that 
the FCN3 gene of the rat is also a non-expressed gene [18]. FCN3 may have been turned into a 
non-expressed gene during evolution in species other than humans. So far, no homologue to the 
human Ficolin-3 has been identified in any species. The significance of the loss of Ficolin-3 in 
species outside the human situation is currently not understood [17].  
2.1.0 Ficolin structure and distribution 
The ficolin genes encode similar polypeptide chains containing an N-terminal region rich in 
cysteine residues, a collagen-like domain with repeats of Gly-Xaa-Yaa segments of varying length 
(where Xaa and Yaa represent any amino acid), a neck region followed by the FBG domain (figure 
3) [15]. Three identical polypeptide chains of 34-35 kDa are assembled into structural subunits by 
interactions of the collagen-like domains [6]. These subunits are then further assembled into higher 
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oligomeric forms through disulfide bridges in the N-terminal region. The “active” ficolin molecule 
in serum is composed of four or more subunits (trimers) linked together. In serum, Ficolin-1 and 
Ficolin-2 primary exists as a 12-mer structure whereas Ficolin-3 primary exist as an 18-mer 
structure [5, 6]. The overall structure resembles the bouquet-like structures known from MBL and 
C1q (figure 3) [6]. The FBG domain is a highly conserved structure, it is similar to the C-terminal 
region of the fibrinogen ! and ! chains and furthermore the FBG domain is found in tenascins and 
in the microfibil-associated protein [18]. In the horseshoe crab Tachypleus tridentatus the 
tachylectins 5A and 5B contain a C-terminal FBG domain that is highly homologous to ficolin 
FBG domain [18]. The tachylectins bind and agglutinate Gram-negative and Gram-positive bacteria 
indicating the pivotal role of the FBG domain in innate immunity [18]. In the ficolins, the FBG 
domain is responsible for ligand recognition, and the formation of trimeric subunits increases the 
affinity for sugar molecules. Further oligomerization of the trimers into multimers ensures high-
affinity binding to sugar residues typically present on microorganisms [1, 5]. When ficolins binds 
to ligands, MASPs situated in the collagen-like domain activate the lectin pathway of the 
complement system. Furthermore, ficolin can also acts as opsonin, facilitating phagocytosis. 
 
 
 
Figure 3: Structural organisation of the ficolins. The ficolin polypeptides contain a short N-terminal cysteine rich 
region, a collagen-like domain, a short linker region, and a C-terminal FBG domain. Ficolins become oligomerized into 
trimers, which are further oligomerized into higher oligomeric forms. The FBG enable the proteins to bind to specific 
carbohydrates and subsequently the collagen-like domain associates with MASPs and thereby activate the lectin 
pathway of complement [18]. 
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Ficolin-1, Ficolin-2 and Ficolin-3 are protein products of the genes FCN1, FCN2 and FCN3, 
respectively. In humans FCN1 and FCN2 are located back-to-back on chromosome 9q34 whereas 
FCN3 is located on chromosome 1p36.11 [19]. FCN1 contains nine exons, whereas FCN2 and 
FCN3 each contain eight exons. The exon organization of FCN1 and FCN2 is similar, although 
FCN1 contains an extra exon, encoding an additional segment of four Gly-Xaa-Yaa repeats [6]. 
The ficolin genes have a general structure and as an example the gene locus of FCN2 is described. 
In FCN2 the first exon encodes the 5’UTR, a signal peptide and N-terminal region. The second and 
third exons encode the collagen-like domain. The fourth exon encodes a short neck region. The 
fifth to eighth exons encode the FBG domain of the molecule and the 3’UTR [6].  
 
The Ficolin-1, Ficolin-2 and Ficolin-3 are polypeptides chains of 326, 313 and 299 amino acids, 
respectively. Ficolin-1 and Ficolin-2 are 80% homologous at the amino acid level, whereas Ficolin-
3 is approximately 40% homologous to Ficolin-1 and Ficolin-2 [20]. 
 
Ficolin-1 is primary expressed in peripheral blood leucocytes: monocytes and granulocytes, and in 
bone marrow. A minor expression of Ficolin-1 is also observed in the spleen and the lung [15]. 
Ficolin-1 is found to be tethered to the cell surface of monocytes and granulocytes, through its FBG 
domain [21]. The ligand recognized by cell surface Ficolin-1 is sialic acid [21]. Interestingly, 
Ficolin-1 expression is downregulated during monocyte differentiation and is not detectable on 
macrophages or monocyte-derived dendritic cells [16, 22]. Ficolin-1 was originally thought to be a 
non-serum protein that exerted its function locally in the tissue. However, it was recently shown 
that Ficolin-1 is found in serum but in a much lower concentration (<0.1!g/ml)
 
compared to 
Ficolin-2 and Ficolin-3 [10]. 
 
Ficolin-2 is predominantly expressed in the liver and it is found in human serum with a mean 
concentration of 5!g/ml [10, 15]. Interestingly, several Single Nucleotide Polymorphisms (SNPs) 
in the promoter region of the FCN2 gene have been shown to regulate the serum concentration of 
Ficolin-2 [20, 23] (section 2.5). 
 
Ficolin-3 is expressed in liver and lung, but also in heart, kidney, spleen, pancreas and placenta 
[15]. Ficolin-3 expression in the lung exceeds the expression in the liver, suggesting a role in lung 
defence. Ficolin-3 is synthesized in the liver by hepatocytes and in the lung by lung alveolar type II 
cells and non-ciliated bronchial epithelial cells [15]. The latter secrete Ficolin-3 onto the epithelial 
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surface, indicating that Ficolin-3 plays a role on mucosal surfaces [22]. Ficolin-3 is an abundant 
serum protein, with a mean concentration of 25!g/ml [10, 22, 24]. 
 
 FCN1 FCN2 FCN3 
Protein name Ficolin-1 
or 
M-ficolin 
Ficolin-2 
or 
L-ficolin 
Ficolin-3 
or 
H-ficolin 
Chromosome 9p34 9p34 1p36.11 
Exon 9 8 8 
Tissue expression Leukocytes Liver Liver and Lung 
Serum concentration (!g/ml) <0.1 5 25 
Table 1: A schematic overview of the FCN1, FCN2 and FCN3 genes. 
 
2.2.1 Ligand specificity of the ficolins 
In the ficolins, the lectin activity is located in the FBG domain of the molecules. Whenever ficolins 
bind to theirs ligands it may activate the lectin pathway of complement or function as an opsonin, 
facilitating phagocytosis. The human ficolins share common affinities towards negatively charged 
carbohydrates such as N-acetyl-D-glucosamine (GlcNAc) and other acetylated compounds, but 
their biological functions are not systemic due to their tissue distribution. In addition, the individual 
ficolins also display a great deal of variation in their binding-patterns [25].  
 
Ficolin-1 binds to acetylated carbohydrates such as GlcNAc and N-acetyl-galactosamine 
(GalNAc). This binding specificity is due to the presence of the acetyl groups, rather than the 
carbohydrate structures. Ficolin-1 functions as an opsonin towards Gram-negative bacteria such as 
Escherichia coli and Salmonella typhimurium [25]. 
 
Ficolin-2 binds Gram-positive bacteria such as serotype III of Group B Streptococci (GBS), due to 
the presence of GlcNAc in the capsular polysaccharide. Ficolin-2 can thus play a critical role in 
preventing neonatal GBS infection [22]. Ficolin-2 also binds to lipoteichoic acid (LTA) from 
Gram-positive bacteria such as Staphylococcus aureus, Streptococcus agalactiae, Bifidobacterium 
animalis, Streptococcus pyogenes and Bacillus subtilis [22]. Like Ficolin-1, Ficolin-2 displays an 
opsonin effect towards the Gram-negative bacteria Escherichia coli and Salmonella typhimurium. It 
is also demonstrated that Ficolin-2 can bind to some capsulated Staphylococcus aureus and 
Streptococcus pneumoniae serotypes but not to non-capsulated strains [22]. 
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Recently, the crystal structure of the FBG domain of the ficolins was resolved. These data showed 
that in addition to the S1-binding site shared by Ficolin-1 and Ficolin-3, the FBG domain of 
Ficolin-2 contained three binding sites (S2-S4) and may therefore have a broader binding 
specificity [25]. 
 
Ficolin-3 binding to bacteria has been examined but so far only Aerocococcus viridans has shown 
significant binding [25]. Ficolin-3 is known to recognize apoptotic Jurkat cells [26]. Furthermore, 
D-fucose, galactose and acetylated bovine serum albumin (acBSA) have been found to function as 
ligands for Ficolin-3. Ficolin-3 is the only molecule resistant to bacterial collagenase among the 
known collagen-like defense proteins [15].  
 2.2.2 Ficolins and apoptosis  
Apoptosis or programmed cell death plays an important role in the maintenance of tissue 
homeostasis. Apoptosis is a controlled process in which cells play an active role in their own death.  
Furthermore, host-cells infected with virus are removed by apoptosis by cytotoxic T-lymphocytes, 
which prevent spreading of the infection. Necrosis, by contrast, is a process in which uncontrolled 
cell death leads to lysis of cells and release of harmful chemicals into the surrounding tissue giving 
rise to inflammatory responses that potentially can lead to serious health problems.  
 
Dysfunction in the molecules important for the removal of dying host cell might be involved in the 
pathogenesis of human diseases. Ficolins seems to play a role in disposal of dying, apoptotic or 
altered cells. Ficolin-2 and Ficolin-3 were shown to bind to late apoptotic and necrotic cells, and 
this recognition results in clearance of the dying cells by phagocytes. This process seems to be 
independent of complement activation [22]. This indicates that the ficolins contain receptor sites for 
phagocytes, which are then capable of initiating opsonophagocytosis. Like MBL and C1q, the 
ficolins possibly mediates opsonophagocytosis through the calreticulin-CD19 receptor complex 
present on the surface of phagocytes [22]. Ficolin-3 seems to be a more powerful opsonin than 
Ficolin-2. Another possible mechanism is that DNA on permeable dying cells functions as ligand 
for Ficolin-2 [22]. Ficolins provide an effective mechanism of clearance of apoptotic or altered 
cells without causing inflammation. However, the exact mechanisms of how the ficolins mediate 
opsonophagocytosis and which ligands on the surface of apoptotic cells are involved, still needs to 
be clarified.  
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2.2.3 FCN gene variations and diseases 
The genes encoding the ficolins are polymorphic and certain SNPs may influence serum 
concentration, structure and function of the individual ficolin molecules, which may have 
pathophysiological relevance in various disease conditions. Several studies have shown that 
dysfunction or abnormal expression of ficolins may play crucial roles in the pathogenesis of human 
diseases including infectious and inflammatory diseases, e.g. recurrent respiratory infections, 
apoptosis and autoimmune disease. Whether these diseases are linked to FCN polymorphisms still 
remains to be elucidated.  
 
FCN1: In the FCN1 gene a total of 45 DNA variations have been identified with large race-related 
differences [27]. Of these variations, four resulted in amino acid substitution (Gly43Asp, 
Arg93Gln, Trp279stop and Gly303Ser) (Figure 4). The variant Gly43Asp and Arg93Gln are 
located in the collagen-like domain and computational analysis showed that Gly43Asp affects the 
second Gly-Xaa-Yaa repeat in Ficolin-1 and may therefore prevent the correct folding of the higher 
orders of oligomers, causing protein instability and reduced protein concentration. The incomplete 
oligomerization may reduce the binding capacity towards ligands. Furthermore, this amino acid 
exchange may also effect the interaction with MASPs [27]. Interestingly, a stop codon is introduced 
in the Trp279stop variation, which results in a reduction of 48 amino acid in the FBG domain 
compared to the wild-type. This variation could likely be influencing the folding and ligand binding 
of the protein. One could speculate that individuals homozygous for this variant may not have 
functional Ficolin-1 and thus be predisposed to certain infectious conditions [27]. Computational 
analysis predicted the Gly303Ser variant, which is located in the FBG domain, to have functional 
effect on ligand binding.  
 
Interestingly, a study linked two SNPs, one located in the promotor region (-1981) and the other a 
synonymous variant in exon 9 position +7919, to be associated with susceptibility to the 
development of rheumatoid arthritis [28]. Another study showed that premature children with 
adverse outcome of necrotising enterocolitis had significantly lower levels of Ficolin-1 compared 
with survivors [29]. Furthermore, it was published that infants with low Ficolin-1 levels more often 
required assisted ventilation than those infant with high Ficolin-1 levels [18]. The two last 
mentioned studies have not been evaluated in relation to inter-individual genetic differences. 
 
FCN2: In the FCN2 gene at total of 36 DNA variations have been identified. Some of these are 
specific for different ethnic groups while others are broadly distributed [27]. In the promoter region 
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of FCN2 three SNPs (-986, -602 and -4) were found to influence the serum concentration [23]. In 
the coding region of FCN2 nine amino acid substitution were found (Arg103Cys, Gly117Met, 
Thr137Met, Arg147Gln, Arg157Gln, Ala185Thr, Thr236Met, Ala258Ser and Ala264fs) (Figure 4). 
The Arg103Cys variant may interfere with the disulfide patterns of the protein. Based on 
computational analysis it was shown that the Thr137Met variant may influence the properties of the 
protein [27]. The variants Arg147Gln and Arg157Gln are located in the S2- or S3-binding site, 
respectively. These variants may affect the interactions with ligands. The two variants Thr236Met 
and Ala258Ser are associated with either increased or decreased GlcNAc-binding. The Ala258Ser 
variant showed elevated binding capacity to GlcNAc compared to the wild-type, whereas the 
variant Thr236Met showed reduced GlcNAc binding [20]. Furthermore the Thr236Met show 
reduced binding capacity towards pentraxin 3 and Aspergillus fumigatus [30]. The frame-shift 
mutation Ala264fs, causes an amino acid alterations, which give rise to a reduction of 39 amino 
acids before termination in the C-terminal part of the Ficolin-2 polypeptide compared to the wild-
type. Individuals homozygous for this variation may express a truncated protein that likely does not 
bind to ligand and may thus give rise to a Ficolin-2 deficiency [20]. Despite all these variations, no 
individuals completely deficient for Ficolin-2 have been described.  
 
FCN2 polymorphisms have been studied in relation to invasive pneumococcal disease in adults and 
self reported respiratory infections in children, but no associations were found [31, 32]. Another 
study found an association between the FCN2 promoter polymorphisms (-986, -602 and -4), which 
are known to have the lowest Ficolin-2 expression, and chronic rheumatic heart disease [33]. In 
contrast, an FCN2 haplotype that is associated with high Ficolin-2 levels has been observed to have 
a protective effect on clinical leprosy [34]. 
 
FCN3: In the FCN3 gene only thirteen DNA variations have been identified, that all are present in 
very low frequencies [27]. Of these thirteen variations five made an amino acid substitution 
(Leu12Val, Leu117fs, Thr125Ala, Glu166Asp and Val287Ala) (figure 4). The variant Val287Ala is 
located in the S1-binding site and may therefore affect the ligand binding. The Leu117fs variant 
creates a premature stop codon in exon 5, which disrupts the pattern recognition domain and may 
result in a novel immunodeficiency, which in turn may predispose homozygous individuals to 
increased risk of infection. Recently, a patient homozygous for this variation was found [10] 
(section 2.2.4).  
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Elevated Ficolin-3 level has been found in SLE patients [35], ovarian cancer [36] and in prostate 
cancer [37], but these studies have not been evaluated in relation to inter-individual genetic 
differences. 
 
 
Figure 4: Location of non-synonymous variants in the human FCN genes. Illustration of the exons and domain 
organisation of the FCN1, FCN2 and FCN3 genes. Black vertical lines above the illustrated genes separate exon 
regions. The genetic variations leading to amino acid changes are shown below the genes. The non-synonymous 
variations are shown in a representative oligomeric 12-mer structure of the ficolin, illustrating that most SNPs are 
clustered in the FBG domains [18]. 
 
2.2.4 Immunodeficiency associated with Ficolin-3 deficiency  
Recently, a patient homozygous for the frameshift mutation L117fs (FCN3 + 1673delC) was 
described. The index patient was a 32-year-old man, who had suffered from frequent lower 
respiratory tract infections, from early childhood. Recurring warts on the patients’ fingers were 
observed from the age of 17. At the age of 20, the patient’s spleen was removed because of 
unexplained thrombocytopenia, from which he fully recovered. At the age of 26, the patient was 
hospitalised for treatment of bilateral frontal cerebral abscesses with non-hemolytic streptococci 
and since then the patient has had grand mal seizures. During the last 8 years, the patient had 
suffered repeated bacterial pneumonia with Haemophilus influenzae and Pseudomonas aeruginosa, 
which required hospital admission. A computed tomography scan of the patient chest revealed 
severe bronchiectasis and pulmonary fibrosis. Furthermore, lung-function test revealed 
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progressively decreased lung capacity and obstructive lung disease. The index patient was screened 
for immunodeficiencies, but no obvious immunologic defects were detected [10]. 
Patients with normal FCN3 genotype, patients heterozygous for the variant or the homozygous 
index patient had a mean serum concentration of 37.5!g/ml, 14.1!g/ml and 0!g/ml, respectively. 
This finding indicates that heterozygous carriers in general have a 50% reduction in Ficolin-3 
serum concentration and the individual homozygous for the L117fs variant has a complete Ficolin-
3 deficiency that likely is associated with chronic infections and disabling lung function. Transient 
functional Ficolin-3 deficiency may also occur in SLE patients as a result of the presence of 
Ficolin-3 autoantibodies [10]. 
 
The L117fs frameshift mutation located in exon 5, results in an altered amino acid composition of 
the C-terminal part of the molecule spanning from residue 117 to a premature stop codon at residue 
180 thus giving rise to a putative truncated form of Ficolin-3 (figure 5). Experiments with 
recombinant expression of the L117fs protein demonstrated that the truncated protein could not be 
expressed [10].  
 
 
Figure 5: The monomeric-domain structure of FCN3 wild-type and the effect of the l117fs mutation. The L117fs 
mutation is indicated by a red dot, which results in nonsense sequence from residue 117 and a premature stop-codon at 
residue 180 [10].  
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3. Aims of the project 
 
Many aspects regarding the FCN genes in human and primates are poorly understood or have not 
yet been investigated. The two main purposes of this thesis are to investigate the following:   
 
1. Characterization of the FCN genes in non-human primate species. Until now, the focus has 
been on the human FCN genes; no information about the FCN genes in other primates 
exists. I aim to identify and characterize the FCN1, FCN2 and FCN3 genes in different 
primate species and furthermore to investigate whether the corresponding Ficolin-1, 
Ficolin-2 and Ficolin-3 are present in primate serum.  
 
2. Genetic variations in the human FCN genes may play a role in different diseases involving 
the ficolin-mediated complement lectin pathway. Several variations in the human FCN 
genes have been identified by Hummelshøj, T. [27]. So far, their functional consequences 
have not been investigated. One of the aims of this project is to produce and characterize 19 
different human FCN-variants and investigates whether they have an effect on protein 
structure and function. The selected variations resulted in an amino acid exchange in the 
protein.   
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4. Materials and Methods 
In the following chapter materials and methods used in this thesis are described. First, the theory 
behind the used methods will be introduced, followed by the actual experimental procedure. 
Detailed protocols for materials and methods are found in Appendix 9.3.   
4.1.0 Theory behind Methods 
 
4.1.1 Polymerase Chain Reaction 
Polymerase Chain Reaction (PCR) is used to amplify a specific DNA sequence using upstream and 
downstream primers complementary to the sequence to be amplified. The PCR reaction is a cyclic 
reaction based on three steps: denaturing, primer annealing and elongation. It is repeated in an 
automated thermal cycler amplifying the PCR product. Primers for PCR are generally designed to 
be 20-30 bp long and ideally containing equal quantity of GC and AT with equal melting 
temperature. To prevent formation of artefacts the primers should contain a G or C in the 3’-
terminal end. When designing primers “primer dimer” and formation of self-annealing should be 
avoided (annealing of the two primers due to complementary structures).  
 
The first step in the PCR reaction is denaturing of the genomic DNA. When genomic DNA is 
heated to 94°C the hydrogen bonds between the genomic DNA strands break and leave two single 
stranded DNA strands. The temperature is lowered to 50-65°C allowing the primers to anneal. 
When raising the temperature to 72°C elongation of the template is performed using 
deoxynucleotide triphosphates (dNTPs) as building blocks and a heat-stable DNA polymerase. The 
products are two new double strands of DNA, both identical to the original. The three steps of the 
PCR cycle are repeated 30 times or more. Each cycle doubles the amount of DNA synthesized in 
the previous cycle. The PCR product can be separated by polyacrylamide gel electrophoresis and 
directly visualized after staining with ethidium bromide. 
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4.1.2 Sequencing 
The dideoxy sequencing method utilizes fluorescent-labelled dideoxynucleotide triphosphates 
(ddNTPs). Like PCR repeated cycles of denaturation, annealing and elongation steps are 
performed, but only a linear amplification is obtained since only a forward primer is used. In this 
work, a biotinylated forward T7-primer was used. This primer binds to a T7-sequence (5’-
taatacgactcactataggg-3’) incorporated in the PCR product to be sequenced. Elongation is carried 
out in a reaction mixture containing DNA template, forward T7-primer, a heat-stable DNA 
polymerase, unlabeled dNTPs and a small fraction of fluorescent labelled ddNTPs (A, T, G and C). 
ddNTPs are derivates of the normal dNTPs but lack the 3’ hydroxyl group. Under elongation 
ddNTPs will randomly be incorporated into the growing chain and terminated due to the lack of the 
3’hydroxyl group, which is necessary to form a phosphodiester bond with the next dNTP. The 
ddNTPs will be incorporated at every possible positions resulting in tagged fragments of all 
possible lengths. 
 
The 3130xl Genetic Analyzer use automated capillary gel electrophoresis to separate each fragment 
according to their sizes and a laser monitors the fluorescent ddNTP-tags on the fragment. Each 
ddNTPs emit a distinct light at different wavelengths. The computer creates an eletropherogram of 
the DNA sequence as a plot of the colours detected from the smallest to the largest fragment (figure 
6).  
 
Figure 6: The principle behind creation of an electropherogram. Figure modified from [38, 39] 
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4.1.3 ELISA 
Enzyme-linked immunosorbent assay better known as ELISA is a widely used technique to 
qualitative or quantitative analysis for antigens or antibodies in a given sample. The specificity and 
affinity of the used antibodies determines the sensitivity of the ELISA. In this project two ELISA-
methods were used: Sandwich ELISA and indirect ELISA. Sandwich ELISA is used to measure the 
concentration of the ficolins in primate sera and in cell supernatant with expressed recombinant 
ficolins (rficolins). Indirect ELISA is used for functional binding studies of rficolins. 
 
The basic principle is that a microtiter plate is coated with a capture antibody in sandwich ELISA 
or a ligand in indirect ELISA (figure 7). After each incubation step a wash step with a mild 
detergent solution is necessary to remove weakly bound components and/or excess amounts of 
antibody, antigen or ligand. When the sample containing the antigen to be measured (the analyte) is 
added, it binds to the capture antibody or to the ligand. A detection antibody is added which binds 
to the analyte. The detection antibody is often a biotin-labelled antibody. Streptavidin horseradish 
peroxidase (HRP) is now added and binds to the detection antibody. Finally, adding OPD (o-
phenylenediamine dihydrochloride (a hydrogen donor) and H2O2 (the substrate for HRP), yields a 
yellow colour that can be measured at 490nm. By comparing the OD-values with a standard curve 
obtained from samples with defined amounts of analyte, the amount of the antigen in the sample 
can be calculated.  
.  
 
 
      A       B      C       D         E            A    B     C       D          E 
 
Figure 7: Indirect and Sandwich ELISA: A) coated with capture ligand or antibody (Ab), B) binding of target 
antigen (Ag) C) detection of target Ag with a biotin-labelled antibody D) binding of Streptavidin-horseradish 
peroxidase (HRP) and E) detection with OPD substrate.  
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4.1.4 SDS-PAGE subjected to Western immunoblotting 
SDS-PAGE subjected to Western immunoblotting is a method to detect specific proteins in a 
sample by using specific antibodies to bind and detect the desired proteins. Proteins are separated 
by gel electrophoresis and subsequently blotted onto a nitrocellulose membrane optimised for 
binding proteins. To avoid non-specific binding of protein after transfer from the gel, the membrane 
is incubated with dry-milk and Tween-20. This step prevents detection antibodies (which also are 
proteins) to bind to the membrane. The antibodies will thus only bind to the epitope on the specific 
protein. A secondary antibody linked to HRP is added and will bind to the primary antibodies. 
Adding enhanced chemiluminescence substrate (hydrogen peroxide and luminol), which is a 
substrate for peroxidase, a chemical reaction occurs due to oxidizing luminol to 3-aminophthalate. 
This reaction produces luminescence at 428nm that can be detected by photographic films. The 
produced luminescence is proportional to the amount of protein attached to the membrane (figure 
8). 
 
 
Figur 8: The principle behind Western Immunoblot [40] 
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4.1.5 Total complement system screen (Wielisa) 
Total Complement System Screen is an ELISA-based method to screen for deficiencies of 
complement components. Microtiter strips are coated with specific activators for each of the three 
complement pathways in combination with a specific buffer so that only activation of the particular 
pathway occurs up to formation of MAC. For the classical pathway human IgM is used as the 
coated activator and for the alternative pathway bacterial LPS is used. For the MBL pathway 
mannan is used (figure 9), which is a specific ligand for MBL but not for the ficolins. Therefore, 
this assay does not screen for deficiencies in the ficolins. For all three pathways complement 
activity is detected with an alkaline phosphatase conjugated monospecific antibody against a 
neoepitope expressed during MAC-formation (C5b-9). The optical density (OD 405nm) correlates 
with the complement activity. Complement defects can be identified from the results of the three 
pathways performed in parallel (table 2). 
 
Figure 9: The principle of the Total Complement system screen assay. Microtiter plates are coated with Human 
IgM, Mannan or bacterial lipopolysaccharides (LPS) to activate the Classical, MBL or Alternative pathway of 
complement, respectively. The complement activation is detected with a monospecific antibody against the MAC-
complex (C5b-9). Figure modified from [41]. 
Classical 
pathway 
MBL 
pathway 
Alternative 
pathway 
Possible complement 
factor deficiency 
Positive Positive Positive None 
Negative Positive Positive C1q, C1r, C1s 
Positive Positive Negative Properdin, Factor B or D 
Positive Negative Positive MBL, MASP-2 
Negative Negative Negative C3, C5, C6, C7, C8, C9 
Negative Negative Positive C4, C2 or combination 
Table 2: Evaluation of the result from the Total complement system screen 
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4.1.5 Site-Directed Mutagenesis 
Site-directed mutagenesis is a simple way to create a mutation in a defined site in an entire plasmid 
using PCR-like technique and mutagenic primers. This method can be used to analyse complex 
relationships between protein structure and function and for studying gene expression.  
 
Knowing the wild-type DNA sequence of the insert of interest, complementary mutagenic primers 
can be designed containing the desired mutation. Extension of the primers generates mutated 
plasmid containing staggered nicks. Under PCR cycling mutagenic plasmids, parental plasmid and 
a combination of both are generated. Parental methylated and hemimethylated plasmids are 
eliminated by enzymatic digestion with a specific restriction enzyme for methylated DNA. Mutated 
plasmid that is unmethylated because it is generated in vitro, is preserved. The mutated plasmid is 
transfected into competent E.coli for nick repair. 
 
4.1.6 Production of recombinant human ficolins in Chinese hamster 
ovary (CHO) cells 
 
This expression system was chosen due to previous successful expression of recombinant human 
ficolin proteins in our laboratory. 
 
Using an expression system that is based on transfection with a selectable marker gene linked to a 
non-selectable gene of interest, a high-level expression of the desired gene can be obtained. The 
pEDdC vector utilizes this expression system. The pEDdC vector carries a cloning sequence for 
insertion of the gene of interest followed by the selective and amplifiable marker gene 
dihydrofolate reductase (dhfr), which is essential for intracellular folate metabolism and DNA 
synthesis. 
 
The cell line used for transfection was CHO DG44 (Chinese Hamster Ovary cells), which is a 
mutant clone that contains no copies of the hamster dfhr gene. Theses dfhr- CHO cells are unable to 
convert folate to tetrahydrofolate, a biocatalyst required for de novo synthesis of purines and 
pyrimidines. Survival can be sustained by adding nucleotide precursors in the media such as 
hypoxanthine and thymidine. Integration of the pEDdC vector, which carries a functional dhfr gene 
and the gene of interest, into the dhfr- CHO DG44 genome enables the cells to grow in a culture 
medium without hypoxanthine and thymidine. Hence, culture medium lacking theses nucleotide 
precursors is used for the selection of cells after transfection of the pEDdC vector. 
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A pSV2neo vector was co-transfected with the pEDdC vector into the CHO DG44 cell line. The 
pSV2neo vector contains the selectable marker neomycin that confers geneticin (G418) resistance 
to eukaryotic cells. Using geneticin (G418) allows for initial selection of positive transfectants. 
When the cells have resumed logarithmic growth, cellular resistance to methotrexate (MTX) is 
mediated stepwise by increasing the concentration of MTX in the culture medium to a final 
concentration of 200nM. MTX is a folic acid analogue that inhibits the activity of dihydrofolate 
reductase stoichiometrically. In order to survive the cells are forced to undergo genomic 
rearrangements and subsequent gene amplification of the dfhr marker gene as well as the gene of 
interest. Typically, expression levels of 2-5 mg of recombinant protein per litre of culture 
supernatant can be achieved.  
 
 
Figur 10: Cloning system for production of rficolins in Chinese Hamster Ovary (CHO) cells.  
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Experimental procedures 
4.2 Part I: Characterization of the FCN genes in primates 
 
4.2.1 DNA sequencing of the FCN genes 
Exons and intron-exon boundaries (ten nucleotides located before and after the coding region) were 
sequenced for FCN1, FCN2 and FCN3 genes on genomic DNA templates from two chimpanzees 
(Pan troglodytes verus), one gorilla, two orangutans, four rhesus macaques (Macaca Mulatta), four 
cynomolgus macaques (Macaca Fascicularis), two baboons and two common marmosets 
(Callithrix jacchus). Each exon was amplified using a single primer set (table 3), where the forward 
primer contained a 5’-biotinylated T7-sequence (taatacgactcactataggg). PCR amplification was 
performed in a volume of 10µl containing: approximately 0.4µl genomic DNA, 1.0µM of forward 
and reverse primers, 1.7mM MgCl2, 0.7µM dNTP, 3% Glycerol, cresol red and 0.25 units Platinum 
Taq DNA polymerase. PCR reactions were performed at the following cycling parameters: 2 min 
92°C, 30 cycles (30 sec 94°C, 30 sec 62°C, 60 sec 72°C) 5 min 72°C. PCR products were 
sequenced in the forward direction with a 5’ biotinylated T7 sequence primer using the ABI 
BigDye cycle sequencing terminator kit and were subsequently purified using streptavidin 
sepharose beads. Sequence analysis was performed on an ABI Prism 3130xl Genetic Analyzer. The 
DNA sequence were aligned using BioEdit software version 7.0.9.0 and DNA variations were 
confirmed visually from sequence electropherograms. The following reference sequences were 
found using the UCSC Genome Bioinformatics Site: chimpanzee Ficolin-1: chr9:135043171-
13505192), chimpanzee Ficolin-2: chr9:135013642-135020717, chimpanzee Ficolin-3: 
chr1:27605614-27612861, orangutan Ficolin-1: chr9:3714-14502, orangutan Ficolin-2: 
chr9:12722926-12729662, orangutan Ficolin-3: chr1:202975217-202981008, rhesus macaque 
Ficolin-1: chr15:3378237-3386312, rhesus maqacue Ficolin-2: chr15:3408984-3415856, rhesus 
maqacue Ficolin-3: chr1: 30042434-30048405,  marmoset Ficolin-1: 7611:78205-86501, marmoset 
Ficolin-2: 7611:45249-50085 and marmoset Ficolin-3: 1709:299350-303228. Reference sequences 
for the gorilla were found in Ensemble.org; gorilla Ficolin-1: 5995:42,607-52,194, gorilla Ficolin-
2: 5995:16,214-22,737, gorilla Ficolin-3: 8428:57,060-62,627. No reference sequences were found 
for cynomolgus macaques or baboon so as reference sequence the rhesus macaque reference 
sequences were used. 
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Table 3: The FCN1, FCN2 and FCN primers  
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4.2.2 Immunoprecipitation followed by SDS-PAGE and Western immunoblotting 
Serum samples from human and primates (chimpanzee, gibbon, baboon, golden-headed lion 
tamarin, black-handed spider monkey, cotton top tamarin and black and white ruffled lemur) were 
immunoprecipitated for Ficolin-2 but only serum samples from the chimpanzees were 
immunoprecipitated for Ficolin-3. Magnetic dynabeads conjugated with anti-mouse IgG antibodies 
were coated with FCN216, FCN219 and FCN106 or FCN313, FCN309 and anti-hFicolin-3 for 
Ficolin-2 or Ficolin-3 respectively and incubated for two hours at room temperature (RT) or over 
night (O/N) at 4°C. After each incubation step the beads were washed thrice in PBS containing 
0.05% Tween-20. Subsequently 10!l serum was added and incubated for 1h at RT with shaking.  
After a final washing the beads were added to SDS-loading buffer and loaded on SDS-PAGE 
(Protocol 9). 
 
4.2.3 Analysis of serum samples by SDS-PAGE followed by Western immunoblotting 
Human and primate serum samples were diluted in SDS-buffer with or without reducing agent and 
heated for 10 minutes at 90°C. The samples were loaded (10!l for unreduced and 5!l for reduced 
sample) on NuPAGE 3–8% Tris–acetate gels with Tris-Acetate SDS running buffer and 
subsequently the separated proteins were blotted onto nitrocellulose membranes using the XCell II 
Mini-Cell blot apparatus, NuPAGE transfer buffer and Hybond ECL nitrocellulose membrane. The 
membranes were blocked 1h at RT with shaking, using 5% skim milk solution in PBS-T (PBS 
containing 0.05% Tween-20). Afterwards they were washed once in PBS-T and subsequently anti-
hFicolin-2 [0.01!g/ml] and anti-hFicolin-3 [0.01!g/ml] were added and incubated for 1 h at RT 
with shaking. After a brief wash with PBS-T the membranes were incubated 1 h at RT with shaking 
with streptavidin-HRP (1:20.000) diluted in PBS-T. The membranes were washed thoroughly 
before being developed onto autoradiographic films using Supersignal West Femto Maximum 
Sensitivity substrate (Protocol 10).  
 
4.2.4 Complement activation assay 
Microtiter plates were coated with acetylated BSA or BSA (both 5µg/ml) in carbonate buffer 
overnight at 4°C. The microtiter plates were washed thrice in barbital-buffer containing 0.05% 
Tween (barbital-T) and then blocked for 1h with barbital-T. Serum samples were diluted two-fold 
(1:10–1:1280) in barbital-T and incubated for 30 minutes at 37°C. Plates were washed thrice in 
barbital-T and subsequently incubated with rabbit anti-C4c (0.13µg/ml) for 2h at room temperature 
wiht shaking. Plates were washed thrice in barbital-T and incubated with HRP-conjugated anti-
rabbit Ig diluted 1:2000 in barbital-T for 1h at RT with shaking. Plates were washed thrice in 
barbital-T and developed for 10-15 minutes with H2O2 as substrate and OPD as colour reagent. The 
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enzymatic reactions were terminated with 50µl 1M sulphuric acid. The optical density was 
measured at 490 nm (protocol 11).  
 
4.2.5 Total complement system screen 
Serum samples from three chimpanzees were analyzed with the Complement System Screen Kit. 
Serum samples, a blank-, a positive-, and a negative control were diluted 1/101 with Diluent CP for 
the Classical pathway, 1/101 with Diluent MP for the MBL pathway and 1/18 with Diluent AP for 
the Alternative pathway. After 15 minutes incubation, the samples were added in duplicate and 
incubated for 70 minutes at 37°C. The samples were washed thrice with washing solution and 
subsequently conjugate were added and incubated for 30 minutes at RT. The samples were washed 
thrice and subsequently substrate solution was added and incubated for 30 minutes at RT. The 
optical density was measured at 405nm and the %-complement activity ((Sample - negative 
control)/(positive control - negative control) * 100) was calculated (protocol 12). 
 
4.2.6 Quantification of Ficolin-2 and Ficolin-3 serum concentration by ELISA 
Serum Ficolin-2 and Ficolin-3 concentrations were measured in eight individual chimpanzees. For 
Ficolin-2 or Ficolin-3 microtiter plates were coated with FCN216 [1!g/ml] or FCN334 [0.2!g/ml] 
diluted in 1xPBS and incubated O/N at 4°C. The microtiter plates were washed thrice in PBS 
containing 0.05 % Tween-20 (PBS-T). Serum samples were diluted 1:25–1:50 or 1:64-1:640 in 
PBS-T for Ficolin-2 or Ficolin-3, respectively and incubated for 2 hours at 37°C. A normal human 
serum pool was used as a standard, two-fold diluted 1:10-1:1280 or 1:161-1:20.480 for Ficolin-2 or 
Ficolin-3, respectively. Plates were washed thrice in PBS-T and subsequently incubated with 
FCN219-Biotin [0.2!g/ml] or FCN334-Biotin [0.1!g/ml] O/N at 4°C for Ficolin-2 or Ficolin-3, 
respectively. Plates were washed thrice in PBS-T and incubated with Streptavidin-HRP (1:4000) 
diluted in PBS-T for 1/2h at RT with shaking. Plates were washed thrice in PBS-T and developed 
for approximately 10-15 minutes with OPD/H2O2 substrate. The enzymatic reactions were 
terminated with 50µl sulphuric acid. The optical density was measured at 490nm (protocol 13). 
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4.3 Part II: Production of recombinant human ficolins 
 
4.3.1 Construction of FCN expression plasmids 
The pEDdC vectors containing full-length human FCN genes (pEDdC-FCN1, pEDdC-FCN2 and 
pEDdC-FCN3) were made by MD, PhD Ying Jie Ma and kindly donated. For detailed informations 
about these constructs see “Synergy between Ficolin-2 and PTX3 boost innate immune recognition 
and complement deposition” [30]. Furthermore, the mutant CHO-clones containing the variant 
F1T279stop, F2T236M, F2A258S and F3L117fs were also a kindly gift from MD, PhD Ying Jie 
Ma. 
 
4.3.2 Construction of the FCN variants 
The nucleotide sequences for primer designs were obtained from the UCSC Genome 
Bioinformatics Site. Primers were only designed for the genetic variations in the FCN genes that 
gave rise to an amino acid change (table 4). These variations were found by Hummelshøj, T. and 
described in “Functional SNPs in the human ficolin (FCN) genes reveal distinct geographical 
patterns” [27]. 
 
Table 4: Primers used for Site-directed mutagenesis 
  Name Base pos Loc.                          Forward Reverse 
F1G43D +1435 Ex2 GTGGGCCTGGAGGaCTCTGACAAGCTCA TGAGCTTGTCAGAGtCCTCCAGGCCCAC 
F1R93Q +3458 Ex4 CCTCCAGGAGACCaAGGAGAGAAGGGG CCCCTTCTCTCCTtGGTCTCCTGGAGG 
F1T279stop +7929 Ex9 CAGGGAGCCTGGTaGTACGCCGACTGT ACAGTCGGCGTACtACCAGGCTCCCTG 
  
  
  
  
  
F
C
N
1
 
F1G303S +8000 Ex9 GAGAGCTATGCCAATaGTATCAACTGGAGTG CACTCCAGTTGATACtATTGGCATAGCTCTC 
F2R103C +4423 Ex5 CTTCCCAGGCCCGtGTACCTGCAAGGA TCCTTGCAGGTACaCGGGCCTGGGAAG 
F2K106R +4433 Ex5 CCCGCGTACCTGCAgGGACCTGCTAGAC GTCTAGCAGGTCCcTGCAGGTACGCGGG 
F2G117S +4465 Ex5 GCACTTCCTGAGCaGCTGGCACACCATC GATGGTGTGCCAGCtGCTCAGGAAGTGC 
F2T137M +4526 Ex5 CTGTGACATGGACAtGGACGGAGGGGGC GCCCCCTCCGTCCaTGTCCATGTCACAG 
F2R147Q +4957 Ex6 ACAGGTTTTCCAGCaGAGGGTGGATGGC GCCATCCACCCTCtGCTGGAAAACCTGT 
F2R157Q +4987 Ex6 GTGGACTTCTACCaGGACTGGGCCACG CGTGGCCCAGTCCtGGTAGAAGTCCAC 
F2A185T +5070 Ex6 CACGCCCTGACCaCCCAGGGTAGGGC GCCCTACCCTGGGtGGTCAGGGCGTG 
F2T236M +6359 Ex8 GGAGATTCCCTGAtGTTCCACAACAAC GTTGTTGTGGAACaTCAGGGAATCTCC 
F2A258S +6424 Ex8 ACCGGAAATTGTtCTGTGATGTTTCAG CTGAAACATCACaGAACAATTTCCGGT 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
F
C
N
2
 
F2A264fs +6443_44 Ex8 TGATGTTTCAGGGAGaTGGTGGTACAAAAACT AGTTTTTGTACCACCAtCTCCCTGAAACATCA 
F3L12V +34 Ex1 GCCCTCCCTGTGGgTTCTCCTGCTTGG CCAAGCAGGAGAAcCCACAGGGAGGGC 
F3L117fs +1637 Ex5 GAGGGCAGGGCCTCCCAGTCTTTTGTG CACAAAAGACTGGGAGGCCCTGCCCTC 
F3T125A +1663 Ex5 TTGTGACATGGACgCCGAGGGGGGCGG CCGCCCCCCTCGGcGTCCATGTCACAA 
F3E166D +3951 Ex6 TGGCTGGGAAATGAcAATTTGCACCAGCTTA TAAGCTGGTGCAAATTgTCATTTCCCAGCCA 
  
  
  
  
  
  
  
 F
C
N
3
 
F3V287A +5543 Ex8 CAGGCCGTGGTGcGGGCCACCCCTAC GTAGGGGTGGCCCgCACCACGGCCTG 
The small letters in red indicate the mutated nucleotides. 
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The FCN plasmid variants were generated using the QuickChange Lightning Site-Directed 
Mutagenesis kit according to manufacturer’s protocol (protocol 4). As template the pEDdC-FCN1, 
pEDdC-FCN2 and pEDdC-FCN3 constructs were used for generating the desired point mutation in 
the FCN1, FCN2 and FCN3 gene, respectively. Each construct was transformed in ultracompetent 
E.coli and grown O/N at 37°C on selective LB-plates. The used selective LB-plates all contained 
ampicillin/carbenicillin (50!g/ml), IPTG (0.5mM) and X-gal (80!g/ml) unless otherwise stated.  
Single colonies were streaked out and verified by PCR using the following primers:  
 
pED-dC-biotin-forward primer:  5´-TGTGGCAGGCTTGAGATCT-3´  
pED-dC-biotin- revers primer:  5´-CTCGTCAAGAAGACAGGGCC-3´  
 
They where analyzed under the following cycling parameters: 94°C 2min, 35 cycles (94°C 15 sec, 
58°C 20 sec, 72°C 90 sec) and 72°C 5 minutes.  
 
4.3.3 Quantum Prep Plasmid Miniprep Kit 
A single colony was inoculated in 2 ml selective LB-medium and grown O/N at 37°C with shaking. 
Plasmid DNA was purified using Quantum Prep Plasmid Miniprep Kit according to manufacturer’s 
protocol (protocol 5). Correct locations of the point mutations in the constructs were confirmed 
using BigDye terminator cycle DNA sequencing using the following primers: 
 
pEDdC-biotin-forward-primer: 5´-GTGTGGCAGGCTTGAGATCT-3´ 
pEDdC-biotin-reverse- primer: 5´-CTCGTCAAGAAGACAGGGCC-3´ 
FCN1ex4-biotin-primer:   5’-GAGACCGAGGAGAGAAGGG-3’ 
FCN2ex4-biotin-primer:   5´-CCCCAGCCGTGCCTGAC-3´ 
FCN3ex5-biotin-primer:   5´-GAGCTGTTGAGCCAGGGC-3´ 
 
4.3.4 Preparation prior to Transfection 
Transformants with the correct insert were grown in 4 ml selective LB-medium for 8 hours at 37°C 
with shaking. After 8 hours incubation, 1 ml of the cell culture was inoculated in 500 ml selective 
LB-medium and grown O/N at 37°C with shaking. Plasmid DNA was purified using the EndoFree 
Plasmid Maxi Prep according to manufacturer’s protocol (protocol 6). 
 
4.3.5 Lipofectamine Transfection in CHO DG44 cell line 
Untransfected CHO-cells were grown in Iscove’s Modified Dulbecco’s Medium (IMEM) 
supplemented with 10% fetal calf serum (FCS), 0.1 mg/ml Penicillin/Streptomycin, 2mM L-
glutamine, and 1xHT-media supplement (contains hypoxanthine and thymidine) in a 37°C 
humidified atmosphere containing 5% CO2. Cells were trypsinized with 0.05% trypsin in PBS and 
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were seeded to 1.4 x 10
6
 cells in 6 cm Petri dishes on day 0. On day 1 the transfection was 
performed using the Lipofectamine 2000 reagent. The cells were co-transfected with the different 
pEDdC-FCN constructions and the pSV2neo vector in culture medium containing no antibiotics. 
On day 2, cells were moved to T25 flask and antibiotics were added to the culture medium. On day 
3, adding G418 (0,1mg/ml) and omitting HT-media in the culture medium results in G418 resistant 
pool of clones after 10-14 days. When dense, the cells were trypsinized and moved to larger flasks. 
When a dense flask of G418 resistant clones was obtained selection and gene amplification with 
MTX were initiated. At first 50nM MTX was added to the culture medium and when the 
transfectants regained normal growth rate and morphology the concentration of MTX was stepwise 
increased up to 200nM. All the transfectants were subsequently frozen (Protocol 8). 
 
4.3.6 SDS-PAGE and Western immunoblotting 
In order to visualize the oligomerisation patterns of the recombinant ficolins, samples were run on 
3-8% Tris-Acetate gels at 150V, 300mA for 1h (protocol 10) in reduced (5!l) and non-reduced 
(10!l) conditions and subsequently blotted onto a nitrocellulosemembrane run at 30V, 300mA for 1 
h. The membrane was block for 1h in 5% drymilk. As primary antibody FCN106-Biotin [0.2!g/ml] 
was used for Ficolin-1. FCN219-Biotin [0.08!g/ml] and FCN106-Biotin [0.2!g/ml] were used for 
Ficolin-2. FCN309-Biotin [0.15!g/ml] and FCN313-Biotin [0.05!g/ml] were used for Ficolin-3. 
As secondary detection reagent streptavidin-HRP conjugate (1:20.000) diluted in PBS-T were used 
for all three blots. The blot was developed on film using SuperSignal WestFemto. In order to 
visualize the oligomerisation patterns of the F1G303S variant we were forced to concentrate the 
sample prior SDS-PAGE due to low protein concentration in the culture medium. This was done by 
using 25!l magnetic dynabeads conjugated with anti-Mouse IgG antibodies, which were incubated 
with 2!l monoclonal FCN115-V2 [1.21!g/ml] for 2 h at RT with shaking. After a wash step the 
beads were incubated with 5ml culture medium ON at 4°C, shaking. The beads were wash and 
subsequently 50!l LDS-buffer diluted 1:2 in PBS-T buffer were added and the sample were heated 
at 70°C in 10 minutes and 10!l were loaded on SDS-PAGE (protocol 9). The same procedure was 
done for the F1R279stop variant. 
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4.3.7 Quantification of the recombinant ficolin variants by ELISA 
To determine the expression levels of the recombinant ficolin variants in cell supernatants a 
sandwich ELISA was performed (protocol 13). Microtiter plates were coated O/N at 4°C with 
FCN115-V2 [2.0!g/ml], FCN216 [1.0!g/ml] or FCN334 [0.2!g/ml] for Ficolin-1, Ficolin-2 and 
Ficolin-3, respectively. FCN115-V2 was diluted in carbonate butter, while FCN216 and FCN334 
were diluted in 1xPBS-buffer. Samples were added in different concentrations due to different 
expression levels and incubated 3 h at 37°C. As detection antibodies M-ficolin [0.25!g/ml], FCN-
K19-Biotin [0.2!g/ml] or FCN334-Biotin [0.1!g/ml] was used for Ficolin-1, Ficolin-2 and Ficolin-
3, respectively. As secondary antibody anti-rabbit-HRP (1:2.000) diluted in PBS-T was used for 
Ficolin-1 or streptavidin-HRP (1:20.000) diluted in PBS-T were used for Ficolin-2 and Ficolin-3, 
respectively. H2O2 and OPD substrate solution was added to the plates and colour development 
measured at OD 490 nm. 
 
4.3.8 Ficolin-3 binding to acetylated BSA. 
We used an ELISA assay to measure the binding capacity of the rFicolin-3 variants to acetylated 
BSA (acBSA). Microtiter wells were coated with either acBSA or BSA [both 5!g/ml] in carbonate 
buffer. Samples were added in a two-fold dilution starting from 0.8-1.8!g/ml and incubated 3h at 
37°C. Plates were washed and subsequently incubated O/N at 4°C with FCN334-Biotin [0.5!g/ml]. 
As secondary detection reagent streptavidin-HRP (1:20.000) was added and incubated for 1h at 
37°C. H2O2 and OPD substrate solution was added to the plates and colour development measured 
at OD 490 nm (protocol 14). In parallel, the exact Ficolin-3 concentrations of the used starting 
dilutions were measured for the rFicolin-3 variants, as described above. 
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5. Results 
5.1 Part I: Characterization of the FCN genes in primates 
 
5.1.1 The FCN gene variations identified in primates 
The exons and intron-exon boundaries were sequenced for FCN1, FCN2 and FCN3 genes on 
genomic DNA from the following higher and lower primates: chimpanzee, gorilla, orangutan, 
rhesus macaque, cynomolgus macaque, baboon and common marmoset.  
 
Positions of the variations are counted with respect to the human FCN1, FCN2 or FCN3 translation 
start site with the A nucleotide of ATG being position +1. All the described human SNPs were 
found using NCBIs SNP database and reference [27]. The protein sequence for FCN1, FCN2 or 
FCN3 for all the investigated primates are listed in appendix 9.1, and variations are referred to their 
respected IUB codes; R = A or G, Y = C or T, K = G or T, M = A or C, S = G or C, W = A or T 
and N = any base. Due to the small number investigated within each primate species the minor or 
major allele could not be determinated. The exon organisation of FCN1, FCN2 or FCN3 was very 
similar between all the investigated primates and human. Several novel inter-individual variations 
were found in all three FCN genes within each species. These results indicate that all the 
investigated primate species have functional FCN1, FCN2 and FCN3 genes that are closely related 
to the human FCN1, FCN2 and FCN3, respectively. 
5.1.2 FCN1 
A total of 25 variations located in the coding region were found of which twelve made an amino 
acid substitution (table 5.A). These non-synonymous variations were located in chimpanzee 
(Arg93Gln), orangutan (Thr249Met), rhesus macaque (Ile68Val, Ile68Ala, Met162Val, Arg182Trp, 
Gly227Ser) cynomolgus macaque (Gly2Lys, Thr133Pro, Leu141Pro), baboon (Arg72Gly) and 
common marmoset (Gly103Arg). Interestingly, the non-synonymous exon 4 variation Arg93Gln 
found in chimpanzee has previously been described in the human gene.  
 
The human variation in nucleotide position +33G>T (Gly11Gly) is found to be a different 
nucleotide in the gorilla, the baboon and the common marmoset. The gorilla and the baboon has an 
A nucleotide whereas the marmoset has a C nucleotide located in this position. These nucleotide 
differences all code for the same amino acid, glycine (appendix 9.1.1). Moreover, the human 
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variations Asn190Asn and His194His located in exon 7 carries a C to T substitution, corresponding 
to the marmoset situation.  
Table 5A: Genetic variations identified in the FCN1 gene 
  Base pos Ref Var Human Region AA change dbSNP 
Orangutan  -4 G C G UTR -  
Cynomolgus macaque  +4 G A G Exon 1 Glu2Lys  
Cynomolgus macaque  +1433 G A G Exon 2 Glu42Glu  
Rhesus macaque  +1478 C T C Exon 2 Pro57Pro  
Rhesus macaque  +1509 A G G Exon 2 Ile68Val  
Rhesus macaque  +1510 T C T Exon 2 Ile68Ala  
Baboon  +1521 A G A Exon 2 Arg72Gly  
Chimpanzee  +3458 G A G Exon 4 Arg93Gln rs56345770 
Cynomolgus macaque  +3462 A C A Exon 4 Gly94Gly  
Common marmoset  +3487 G A G Exon 4 Gly103Arg  
Cynomolgus macaque  +4785 A C A Exon 6 Thr133Pro  
Cynomolgus macaque  +4787 C T C Exon 6 Thr133Thr  
Cynomolgus macaque  +4810 T C C Exon 6 Leu141Pro  
Rhesus macaque  +5272 A G A Exon 7 Met162Val  
Rhesus macaque  +5283 C T T Exon 7 Ser165Ser  
Cynomolgus macaque  +5283 C T T Exon 7 Ser165Ser  
Rhesus macaque  +5332 C T C Exon 7 Arg182Trp  
Orangutan  +5355 G A G Exon 7 Gly189Gly  
Rhesus macaque  +5395 A G A Intron 8 -  
Orangutan  +6684 T C T Exon 8 Ala226Ala  
Rhesus macaque  +6684 C T T Exon 8 Ala226Ala  
Rhesus macaque  +6685 G A G Exon 8 Gly227Ser  
Orangutan  +6708 T G T Exon 8 Leu234Leu  
Orangutan  +6726 C T C Exon 8 Val240Val  
Orangutan  +7839 C T C Exon 9 Thr249Met  
Cynomolgus macaque  +8020 A C G Exon 9 Ala309Ala  
Orangutan  +8035 C T T Exon 9 Tyr314Tyr  
Abbreviation: Base pos: base position Ref: reference sequence, Var: variation found, Human: human reference 
sequence and AA change: amino acid change. The non-synonymous variations are highlighted in bold. 
 
5.1.3 Disagreements with the reference sequence for the FNC1 gene 
Minor disagreements with the reference sequence were observed in a few primates (table 5B). In 
greater detail, while the reference sequence for the gorilla defined the nucleotide at position +2 in 
exon 1 to be any base (A, T, G or C), we sequenced it to be a C nucleotide (appendix 9.1.1). 
Compared to the human gene, this nucleotide is a part of the initiating codon ATG, coding for the 
amino acid methionine. For the gorilla the situation is different, the nucleotide in position +2 is a C, 
which changes the initiating codon from ATG to an ACG and this codon does not code for the 
initiating amino acid methionine. Instead another initiating site is observed in amino acid residue 8, 
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making the gorilla Ficolin-1 protein seven amino acids shorter in the N-terminal region compared 
to the human case. Searching the NCBI database, no transcript variant was found. 
 
Screening the FCN1 gene in the orangutan, we found an extra C and a G nucleotide located in exon 
2 at position +1451 and + 1472, respectively, which was not contained in the reference sequence. 
When the sequence was aligned with the human FCN1 gene it was found that the latter sequence, in 
agreement with our findings, also have a C and a G nucleotide located in theses positions. In intron 
6, position +5248 we sequenced the nucleotide to be a C for all the investigated rhesus macaques, 
where the reference sequence and the human sequence declare is to be a T nucleotide. In exon 8, 
position +6650 we sequenced the nucleotide to be a T for all the investigated common marmosets, 
where the reference sequence declare a G nucleotide. 
 
Table 5B: Disagreement with the reference sequence in the FCN1 gene 
  Base pos Ref Var Human Region AA change 
Gorilla  +2 N C T Exon 1 Met1Thr 
Orangutan  +1451 dC C C Exon 2  
Orangutan  +1472 dG G G Exon 2  
Rhesus macaque  +5248 T C T Intron 6 - 
Common marmoset  +6650 G T A Exon 8 Ala215Ser 
Abbreviation: Base pos: base position Ref: reference sequence, Var: variation found, Human: human reference 
sequence and AA change: amino acid change. The non-synonymous variations are highlighted in bold. 
 
5.1.4 Comparison of the human and the common marmoset FCN1 genes  
When the marmoset FCN1 sequence is compared with the human FCN1 sequence, several 
interesting findings are observed. Common marmosets, which belong to the new world monkeys, 
are the primate farthest descent from the human situation, analysed in this study. 
 
FCN1 exon 2: Both analysed common marmosets are heterozygous for a human analogue 
sequence and a marmoset reference analogue sequence (figure 11.A). The marmoset analogue has 
an insert of 19 nucleotides between position +1504-1505. This insertion causes a reading frame 
shift, which further causes a premature AMB-stop codon to arise in position +1514. 
 
FCN1 exon 8: At position +6647 an A nucleotide is deleted, which make the amino acid sequence 
go out of reading frame compared to the human situation. Furthermore, two nucleotides are deleted 
at position +6687 and +6693, which make the reading frame go into frame again (figure 11.B). This 
frame shift changes 15 amino acids in the FBG domain before it goes into reading frame again.  
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FCN1 exon 9: At position +7965-7972 eight nucleotides are deleted and moreover in position 
+7986-8000 fifteen nucleotides are deleted. This changes the reading frame and gives rise to a 
premature OPA-stop codon (figure 11.C) making the marmoset protein ten amino acid shorter than 
the human protein.  
 
 
Figure 11: Comparison of the human and the common marmoset FCN1 genes. (A) In exon 1 the investigated 
common marmosets were found to be heterozygote for a human and a marmoset analogue sequence. The marmoset 
analogue sequence has an insertion of 19 nucleotides between position +1504-1505, which causes a reading frame shift, 
and subsequently gives rise to a premature stop codon in position +1514. (B) In exon 8 a nucleotide is missing in 
position +6647, which make the sequence go out of frame. In position +6687 and +6693 a nucleotide is also missing, 
making the sequence go into reading frame again. These deletions changes 15 amino acids in the FBG domain before it 
goes into frame again. (C) In exon 9 eight nucleotides are missing in position +7965-7972 and again 15 nucleotides are 
missing in position +7986-8000, which causes a reading frame shift and give rise to a premature stop codon, making 
the Ficolin-1 polypeptide 10 amino acid shorter in the FBG domain than for the human situation. Figure generated in 
Bio-edit. 
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5.1.5 FCN2 
A total of 19 variations located in the coding region were found, where ten out of the 19 variations 
were found in exon 6. Furthermore, ten non-synonymous variations (table 6.A) were found in 
chimpanzee (Val149Met, Phe155Leu), orangutan (Arg103His, Thr161Ala), rhesus macaque 
(Gly72Arg, Val149Met, Ala185Thr, Glu217Lys, Ser253Asn, Met260Ile), cynomolgus macaque 
(Val149Met, Val227Ala) and common marmoset (Thr161Ala). Of these, the exon 6 variation 
Ala185Thr found in the rhesus macaque has previously been described in human. Furthermore, two 
synonymous variations in exon 6; Asn177Asn found in rhesus macaque and His181His found in 
baboon and common marmoset, have also previously been described in human (figure 6.A). The 
human variation in nucleotide position +1766G>A (Gly54Gly) is found in the common marmoset 
as an A nucleotide, whereas all the other investigated primates has a G nucleotide in this position. 
(appendix 9.1.2). Several novel synonymous variations occurred in more than one primate species, 
this included the variation in nucleotide position +84G>A (Ala28Ala) found in the chimpanzee and 
the baboon, the variation in nucleotide position +4962G>A (Val149Met) found in the chimpanzee, 
the rhesus macaque and the cynomolgus macaque and finally the variation in nucleotide position 
+4998G>A (Thr161Ala) found in the orangutan and the common marmoset (table 6.A). 
Table 6A: Genetic variations identified in the FCN2 gene 
  Base pos Ref Var Human Region AA change dbSNP 
Rhesus macaque +48 G T G Exon 1 Leu16Leu  
Chimpanzee +84 G A G Exon 1 Ala28Ala  
Baboon +84 G A G Exon 1 Ala28Ala  
Cynomolgus macaque +1701 G A G Intron 1 -  
Rhesus macaque +1818 G C G Exon 2 Gly72Arg  
Baboon +1822 C G G Intron 2 -  
Baboon +2544 G A G Intron 3 -  
Baboon +3912 C T T Intron 3 -  
Gorilla +4413 N A/C C Intron 4 -  
Orangutan +4413 T C C Intron 4 -  
Orangutan +4424 G A G Exon 5 Arg103His  
Rhesus macaque +4938 C T T Intron 5 -  
Cynomolgus macaque +4938 C T T Intron 5 -  
Chimpanzee +4962 G A G Exon 6 Val149Met  
Rhesus macaque +4962 G A G Exon 6 Val149Met  
Cynomolgus macaque +4962 G A G Exon 6 Val149Met  
Common marmoset +4967 C T T Exon 6 Asp150Asp  
Cynomolgus macaque  +4973 C T T Exon 6 Ser152Ser  
Chimpanzee  +4982 C A C Exon 6 Phe155Leu  
Orangutan  +4998 A G A Exon 6 Thr161Ala  
Common marmoset  +4998 G A A Exon 6 Ala161Thr  
Common marmoset  +5003 C T C Exon 6 Tyr162Tyr  
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Rhesus macaque  +5048 C T T Exon 6 Asn177Asn rs2274845 
Baboon  +5060 C T C Exon 6 His181His rs34789496 
Common marmoset  +5060 C T C Exon 6 His181His rs34789496 
Common marmoset  +5069 C T C Exon 6 Thr184Thr  
Rhesus macaque  +5070 G A G Exon 6 Ala185Thr rs55860122 
Orangutan  +5688 C T C Exon 7 Ala213Ala  
Rhesus macaque  +5698 G A G Exon 7 Glu217Lys  
Cynomolgus macaque  +5729 T C T Exon 7 Val227Ala  
Rhesus macaque  +6410 G A A Exon 8 Ser253Asn  
Rhesus macaque  +6432 G A G Exon 8 Met260Ile  
Abbreviation: Base pos: base position Ref: reference sequence, Var: variation found, Human: human reference 
sequence and AA change: amino acid change. The non-synonymous variations are highlighted in bold. 
 
5.1.6 Disagreements with the reference sequence in FCN2 gene 
Some disagreements were found between the reference sequence and our findings. However, we 
showed that all our findings were in agreement with the human nucleotide sequence (table 6.B).  
 
Table 6B: Disagreement with the reference sequence in the FCN2 gene 
  Base pos Ref Var Human Region AA change 
Rhesus macaque  +84 A G G Exon 1 Ala28Ala 
Chimpanzee  +3940 T C C Exon 4 Leu97Pro 
Rhesus macaque  +4947 A G G Exon 6 Ile144Val 
Gorilla  +4962 N G G Exon 6 Val149Val 
Common marmoset  +5045 A G G Exon 6 Gly176Gly 
Gorilla  +5751 G C C Intron 7 - 
Orangutan  +5023 A G G Exon 6 Gln169Arg 
Orangutan  +5697 A G G Exon 7 Ala216Ala 
Chimpanzee  +6478 G A A Exon 8 Asp276Asn 
Common marmoset  +5073 A C C Exon 6 Arg186Arg 
Common marmoset  +5644-5645 G - - Exon 7  
Common marmoset  +5750 A G G Intron 7 - 
Abbreviation: Base pos: base position Ref: reference sequence, Var: variation found, Human: human reference 
sequence and AA change: amino acid change. The non-synonymous variations are highlighted in bold. 
 
 
 
 
 
 
 
 40 
5.1.7 FCN3 
Only a total of six variations located in the coding region were found, which all made an amino 
acid substitution (table 7.A). These non-synonymous variations were located in the gorilla 
(Gly218Ser) and in the cynomolgus macque (Gly72Ser, Thr125Met, Asp235Gly, Gly251Ser and 
Ala256Gly). In the human FCN3 gene a variation is found in exon 1 at nucleotide position 
+51G>A (Gly17Gly), in this position an A nucleotide was found for the rhesus macaque, the 
cynomolgus macaque and the baboon. The rest of the investigated primate species had a G 
nucleotide located in this position (appendix 9.1.3).  
 
Table 7A: Genetic variations identified in the FCN3 gene 
  Base pos Ref Var Human Region AA change 
Cynomolgus macaque  +846 G A G Exon 3 Gly72Ser 
Chimpanzee  +867 G A G Intron 3 - 
Cynomolgus macaque  +1664 C T C Exon 5 Thr125Met 
Gorilla  +4214 G A A Exon 7 Gly217Ser 
Cynomolgus macaque  +5387 A G G Exon 8 Asp235Gly 
Cynomolgus macaque  +5434 G A G Exon 8 Gly251Ser 
Cynomolgus macaque  +5450 C G C Exon 8 Ala256Gly 
Abbreviation: Base pos: base position Ref: reference sequence, Var: variation found, Human: human reference 
sequence and AA change: amino acid change. The non-synonymous variations are highlighted in bold. 
 
5.1.8 Disagreements with the reference sequence in the FCN3 gene 
Reference sequence disagreements were only observed in the chimpanzee and the rhesus macaque 
(table 7.B). In exon 5, position +1606 we sequenced the nucleotide to be a T for all the investigated 
chimpanzees, similar to the human gene, whereas the reference sequence declares a G nucleotide. 
Also in exon 5, position +1647 we sequenced the nucleotide to be a C for all the investigated rhesus 
macaque, similar to the human gene, whereas the reference sequence declares a T nucleotide.  
 
Table 7B: Disagreement with the reference sequence in the FCN3 gene 
 Base pos Ref Var Human Region AA change 
Chimpanzee  +1606 G T T Exon 5 Gly106Trp 
Rhesus macaque  +1647 T C C Exon 5 Val119Val 
Abbreviation: Base pos: base position Ref: reference sequence, Var: variation found, Human: human reference 
sequence and AA change: amino acid change. The non-synonymous variations are highlighted in bold. 
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5.2. Primate serum analysis 
5.2.1 Oligomerisation pattern of primate Ficolin-2 and Ficolin-3  
To verify if higher and lower primates express Ficolin-2 and Ficolin-3 in serum we performed a 
SDS-PAGE followed by Western blot under reduced and non-reduced conditions. Mono- and 
polyclonal anti-Ficolin-2 or anti-Ficolin-3 was used as detection antibodies for Ficolin-2 or Ficolin-
3, respectively.  
 
Serum Ficolin-2 was detected in the following higher and lower primate species; chimpanzee, 
gibbon, baboon, cotton top tamarin, black and white ruffed lemur and golden-headed lion tamarin. 
The primates showed an identical banding pattern compared to the human protein under both 
reduced and non-reduced conditions (figure 12.A). Under reduced condition the oligomers of 
Ficolin-2 are reduced to single monomers. Unfortunately, the monomer band for the black and 
white ruffled lemur and the golden-headed lion tamarin were not detected under reduced condition, 
probably due to inadequate protein content. Furthermore, we observed that some of the investigated 
chimpanzees had a small extra band located just above the monomers, probably caused by different 
glycosylation of the monomers (figure 12.B).  
 
Figure 12: Oligomerisation pattern of primate Ficolin-2 evaluated by SDS-PAGE and Western blot. Samples 
were analyzed by SDS-PAGE on 3-8% Tris-actetat gels under non-reduced and reduced conditions followed by 
western blot and detected with mono- and polyclonal anti-Ficolin-2. Arrow shows the monomers and the multimers of 
Ficolin-2. 
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Serum Ficolin-3 was detected in the following higher and lower primate species; chimpanzee, 
gibbon, baboon, cotton top tamarin, black and white ruffed lemur and black-handed spider monkey. 
Initially, the protein bands of the chimpanzee Ficolin-3 was very week on the Western blot 
compared to the human and the other primates (data not shown) indicating that the chimpanzee has 
a much lower Ficolin-3 serum concentration than all the other investigated primate species. In order 
to get a stronger signal on Western blot we immunoprecipitated Ficolin-3 in chimpanzee serum. 
The banding pattern for serum Ficolin-3 in higher and lower primate species was identical to 
human Ficolin-3 (figure 13). A slightly lower molecule weight of the oligomers was observed for 
the baboon and the cotton top tamarin.  
 
 Figure 13: Oligomerisation pattern of primate Ficolin-3 evaluated by SDS-PAGE and Western blot. Samples 
were analyzed by SDS-PAGE on 3-8% Tris-actetat gels under non-reduced and reduced conditions followed by 
western blot and detected with mono- and polyclonal anti-Ficolin-3. Arrows shows the monomers and the multimers of 
Ficolin-2 
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5.2.2 Ficolin-2 and Ficolin-3 serum concentrations in chimpanzees 
In order to determine the serum concentrations of Ficolin-2 and Ficolin-3 in chimpanzees a 
sandwich ELISA, originally designed for human serum analysis, was performed on serum from 
chimpanzees. Monospecific anti-Ficolin-2 (FCN216 and FCN219) or anti-Ficolin-3 (FCN334) 
antibodies were used as coating and detection antibodies for Ficolin-2 or Ficolin-3, respectively. 
Whole serum was used as a source for ficolins.  
 
The Ficolin-2 serum concentration was measured in eight chimpanzees and ranges from 0.6-
6.8µg/ml, with a mean serum concentration of 3.7µg/ml (figure 14A). These results indicate that 
chimpanzee and human (mean 5µg/ml) seems to have equal amount of Ficolin-2 present in serum.  
 
The Ficolin-3 serum concentration was measured in eight chimpanzees and ranges from 0.3-
2.5µg/ml, with a mean serum concentration of 1.1µg/ml (figure 14B). Chimpanzees seem to have a 
much lower Ficolin-3 serum concentration compared to human with a mean concentration of 
25µg/ml.  
 
These results indicate that the investigated chimpanzees all had detectable Ficolin-2 and Ficolin-3 
in serum.  
(A)                                                       (B) 
 
Figure 14: Ficolin-2 and Ficolin-3 serum concentration in chimpanzee. (A) Individual serum Ficolin-2 
concentrations in eight chimpanzees. (B) Individual serum Ficolin-3 concentrations in eight chimpanzees. Horizontal 
lines indicate medians. 
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5.2.3 Activation of the three complement pathways  
We evaluated if chimpanzees lack any complement components needed to activate and generate the 
MAC formation of the classical, the alternative or the lectin pathway, by performing a Total 
Complement System Screen on whole sera from three chimpanzees. The investigated chimpanzees 
were able to activate and generate MAC formation for all three pathways of the complement 
system and showed no deficiencies in the needed complement components (figure 16). This assay 
do not screen for deficiencies in the ficolins. 
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Figure 15: Screening for deficiencies in complement components. A total complement system screen, an ELISA-
based method, was performed using whole sera from three chimpanzees. For each complement pathway microtiter 
wells were coated with specific activators; IgM, LPS and mannan for the classical, the alternativ or the lectin pathway 
of complement, respectively. Complement activations were detected with a monospecific antibody against neoantigens 
expressed during MAC-formation. None of the analysed chimpanzees showed any deficiencies of complement 
components in any of the three complement pathways. 
 
5.2.4 Complement activation assay.  
It has been demonstrated that incubating human serum with acetylated bovine serum albumin 
(acBSA) results in complement C4-deposition, in contrast to non-acetylated BSA, which does not 
lead to C4-deposition. AcBSA functions as a binding ligand for Ficolin-3, which mediates the 
activation of the lectin pathway of complement [10]. To evaluate if chimpanzee serum also are 
capable of mediating C4-deposition through the lectin pathway, we performed an ELISA assay, 
measuring the C4-deposition. Microtiter wells were coated with untreated BSA or acBSA, washed 
and as a source of complement components chimpanzee or human serum was incubated. C4-
deposition were observed for both chimpanzee and human sera in the wells coated with acBSA 
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(figure 15). In BSA-coated wells a small amount of C4-deposition was observed in the wells 
incubate with the highest serum concentration. 
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Figure 16: Complement activation mediated by chimpanzee serum. Complement activation were analysed in 
relation to C4-deposition. An ELISA assay measuring the C4-deposition was performed. Microtiter wells were coated 
with BSA or acBSA and C4-deposition were detected using anti-C4c, an antibody against neoantigens expressed during 
cleaves of complement component C4 into C4b. Both for the human and the chimpanzee situations C4-deposition were 
only observed in microtiter wells coated with acBSA. A small amount of C4-deposition was observed in wells coated 
with BSA but only in wells incubated with the highest serum concentrations.  
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5.3 Part II: The expression and analysis of rFicolin-1, rFicolin-2 
and rFicolin-3 variants 
5.3.1 Expression levels and oligomeric structures of rficolin variants 
 
In order to make recombinant ficolin proteins, full-length human FCN1, FCN2 or FCN3 cDNA 
were cloned into a pEDdC vector. The pEDdC-FCN1, pEDdC-FCN2 or pEDdC-FCN3 vectors 
served as templates for construction of 19 different pEDdC vectors. Using site-directed 
mutagenesis each pEDdC vector was subjected to a single point mutation. These point mutations 
were located in the cDNA to yield the non-synonymous variations found in the human genome by 
Hummelshøj, T [27]. The following pEDdC vectors were constructed: 
 
Ficolin-1 variants: rFicolin-1, rG43D, rR93Q, rG303S, rW279stop 
Ficolin-2 variants:: rFicolin-2, rR103C, rK106R, rG117S, rT137M, rR147Q,    
                                 rR157Q, rA185T, rT236M, rA258S, rA264fs  
Ficolin-3 variants: rFicolin-3, rL12V, r L117fs, rT125A, rE166D, rV287A. 
 
These 22 different pEDdC vectors were co-transfected with pSVneo into CHO-cells and selected 
with G418. When resistant clones had developed, they were subjected to multiple cycles of 
selection with increasing concentrations of MTX.  
 
The oligomerization patterns of the recombinant proteins were analysed by SDS-page followed by 
western blot. To determine the expression levels of the rFicolin-1, rFicolin-2 and rFicolin-3 
variants an ELISA assay was performed on the culture supernatants. 
 
5.3.2 rFicolin-1 variants: Under non-reduced conditions, SDS-PAGE subjected to western blot 
showed that rFicolin-1 wild-type, rG43D, rR93Q and rG303S were a mixture of monomers and 
oligomers (figure 17.A). Due to the very low expression level of rF1G303S it was necessary to 
immunoprecipitate the protein prior to SDS-PAGE. This procedure was also done for the 
rR279stop variant, but no visual bands were observed, indicating that the protein was not 
expressed. This result is in full agreement with the result obtained by ELISA, where no rR279stop 
protein was detected (figure 17.B). For the expressed rFicolin-1 variants the 12-mer bands seems to 
be the most dominant oligomeric forms and are indicated with an arrow. Weaker bands are seen 
above the 12-mers, indicating that the rFicolin-1 variants are able to form even larger oligomeric 
forms. The oligomeric forms of the rFicolin-1 variants were reduced to a single band under reduced 
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conditions. These patterns are consistent with previous analyses of the Ficolin-1 molecule. The 
levels of the rFicolin-1 variants were not expressed in equal amounts but range from 0-13.6!g/ml 
(figure 17). 
 
 
Figure 17: The oligomerization patterns and the expression levels of rFicolin-1 variants. (A) The recombinant 
proteins were expressed in CHO-cells and subsequently the cell supernatants were analysed on 3-8% Tris-Acetate gels 
under reduced and non-reduced conditions and subjected to western blot using FCN106-Biotin. Prior SDS-PAGE 
rR279stop and G303S were immonoprecipitated using FCN115-V2. Arrowhead indicates the 12-mers. (B) An ELISA 
assay where used to measured the Ficolin-1 concentration in the cell supernatants. FCN115-V2 were coated on a 
microtiter plate, subsequently incubated with the cell supernatants and detected using M-ficolin. 
 
5.3.3 rFicolin-2 variants: Under non-reduced conditions, SDS-PAGE subjected to western blot 
showed that rFicolin-2 wild-type, rR103C, rK106R, rG117S, rT137M, rR147Q, rR157Q, rA185T, 
rT236M and rA258S were a mixture of monomers and oligomers (figure 18.A). The rA264fs 
variant showed no bands indicating that the protein was not expressed, which is in agreement with 
the obtained ELISA result (figure 18.B). For the expressed rFicolin-2 variants the 12-mer bands 
seem to be the most dominant oligomeric forms and are indicated with an arrow. Weaker bands are 
seen above the 12-mer bands, indicating that the rFicolin-2 variants are able to form covalently 
linked larger oligomers. The oligomeric forms of the rFicolin-2 variants were reduced to a single 
band under reduced conditions. These patterns are in agreement with the profile seen for the human 
Ficolin-2 in a normal serum pool. The expression levels of the rFicolin-2 variants were not 
expressed in equal amounts but range from 0-2.0!g/ml (figure 18.B). 
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Figure 18: The oligomerization patterns and the expression levels of rFicolin-2 variants. (A) The recombinant 
proteins were expressed in CHO-cells and subsequently the cell supernatants were analysed on 3-8% Tris-Acetate gels 
under reduced and non-reduced conditions and subjected to western blot using FCN219-Biotin and FCN106-Biotin. 
Arrowhead indicates the 12-mers. (B) An ELISA assay where used to measured the Ficolin-2 concentration in the cell 
supernatants. FCN216 were coated on a microtiter plate, subsequently incubated with the cell supernatants and detected 
using FCN219-Biotin. 
 
5.3.4 Ficolin-3 variants: Under non-reduced conditions, SDS-PAGE subjected to western blot 
showed that rFicolin-3 wild-type, rL12V, rT125A, rE166D and rV287A were a mixture of 
monomers and oligomers (figure 19.A). In agreement with previous results [10] the rL117fs variant 
was not expressed and as a result not detected by ELISA (figure 19.B). For the expressed rFicolin-3 
variants the 18-mers bands seem to be the dominant oligomeric forms and are indicated with an 
arrow. Weaker bands are seen above the 18-mers, indicating that the rFicolin-3 variants are able to 
form even larger oligomeric forms. Ficolin-3 forms several higher oligomeric forms than rFicolin-1 
and rFicolin-2 variants. The oligomeric forms of the rFicolin-3 variants were reduced to a single 
band under reduced conditions. These patterns are in agreement with the profile seen for the human 
Ficolin-3 in a normal serum pool. The expression levels of the rFicolin-3 variants were not 
expressed in equal amounts but range from 0-46.5!g/ml (figure 19.B). 
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Figure 19: The oligomerization patterns and the expression levels of rFicolin-3 variants. (A) The recombinant 
proteins were expressed in CHO-cells and subsequently the cell supernatants were analysed on 3-8% Tris-Acetate gels 
under reduced and non-reduced conditions and subjected to western blot using FCN313-Biotin. Arrowhead indicates 
the 18-mers. (B) An ELISA assay where used to measured the Ficolin-3 concentration in the cell supernatants. FCN334 
were coated on a microtiter plate, subsequently incubated with the cell supernatants and detected using FCN334-Biotin.  
 
5.2 Binding studies of rficolin variants 
In order to analyse if the binding capacity was affected in the rficolin variants, we analysed 
different ligands, know to function as ligands for Ficolin-2 and Ficolin-3. It has been shown that 
acBSA can function as a ligand for Ficolin-3 [10]. We analysed if acBSA also could function as a 
binding ligand for the rFicolin-1 and rFicolin-2 variants. We observed some binding of rFicolin-2 
variants to acBSA (data not shown) but further optimisation of the assay needs to be performed. No 
binding towards acBSA was observed for rFicolin-1 variants (data not shown). Curdlan (1,3-!-D-
glucan) has previous been found to function as a ligand for Ficolin-2 [42]. We were not able to 
reproduce these findings for the rFicolin-2 variants (data not shown).  
5.2.1 rFicolin-3 variants binding to acetylated BSA (acBSA). 
It was shown that acBSA, but not BSA, can function as a ligand for Ficolin-3 [10]. The Ficolin-3 
concentrations in the cell supernatants from the rFicolin-3 variants were diluted in cell supernatant 
for CHO-cells transfected with an empty vector to approximate 1!g/ml. The experiment was 
repeated three times and each time fresh starting dilutions were made and their exact Ficolin-3 
concentrations were established (data not shown). To compensate for sample differences, the ligand 
binding capacity of each rFicolin-3 variant was compared to its respective Ficolin-3 concentration 
and the %-binding capacity towards acBSA was calculated. The rFicolin-3 wild-type was used as a 
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standard and set to have a 100%-binding capacity towards acBSA. The L117fs variant was omitted, 
as it did not show expression. 
 
The binding capacity of the rL12V (82%) and rT125A (71%) variants was similar to the binding 
capacity of rFicolin-3 wild-type (100%) towards acBSA (figure 20). Of particular interest, the 
rE166D variant showed a three-fold increase in binding capacity (330%) towards acBSA compared 
to the rFicolin-3 wild-type (figure 20). This mutation gives rise to a Ficolin-3 protein with an 
abnormal binding capacity towards acBSA and can be defined as a gain-of-function mutation. 
Furthermore, we found that the binding capacity for the rV287A variant towards acBSA, was 
lowered. Compared to the rFicolin-3 wild-type variant, the rV287A variant binds approximately 17 
times weaker (6%) towards acBSA (figure 20.A). The protein function of Ficolin-3 proteins with 
the rV287A mutation has reduced ability to recognize, and bind acBSA and can be defined as a 
loss-of-function mutation. No binding towards BSA was observed for any of the investigated 
rFicolin-3 variants (data not shown). 
 
(A) 
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(B)  
 
Figure 20: rFicolin-3 binding to acBSA. Dilutions of cell supernatants from rFicolin-3 variants were added to ELISA 
wells coated with acBSA or BSA and bound Ficolin-3 was measured using FCN334-Biotin. To compensate for 
differences in Ficolin-3 concentrations, acBSA-binding is given as index values base on ODs (490nm) from the 
acBSA-ELISA assay divided with the Ficolin-3 concentration. A difference in binding profile towards acBSA was 
observed for the investigated variants; E166D showed increased binding capacity towards AcBSA and V287A showed 
decreased binding capacity towards acBSA. The vertical bars indicate standard deviation based on three experiments. 
(A) Shows the %-yield of rFicolin-3 variants towards acBSA, calculated for the 1:8 dilutions (B) Shows the relative 
acBSA-binding divided with the Ficolin-3 concentration. 
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6 Discussion 
6.1 Part I: Investigation of the primate FCN genes and 
respective proteins  
6.1.1 Genetic diversity in primates 
There is a plethora of information in the literature describing mice, pig and mainly human FCN 
genes. This is the first report of a characterization of the FCN genes in higher and lower primate 
species. FCN1, FCN2 and FCN3 genes were investigated for DNA variations in samples from the 
following primate species: chimpanzee, gorilla, orangutan, rhesus macaque, cynomolgus macaque, 
baboon and common marmoset. As in humans, the FCN genes of the investigated primates were 
found to be highly polymorphic and several novel intra-individual variations in all three FCN genes 
within each primate species were found. Due to the few samples analysed within each primate 
species, some variations may be overlooked, for instance in the rhesus macaque where a variation 
was found in the FCN2 gene in position +5048 and this variation may also be present in the other 
investigated primate species (appendix 9.1.2). In order to elucidate if any variation has been 
overlooked, screening of more primate species needs to be conducted. Several reference 
disagreements was observed in all three FCN genes and whether these disagreements reflect real 
variations or are due to errors in the reference sequences in the Pubmed database still remain to be 
elucidated.  
 
Interestingly, several SNPs in the FCN1 and FCN2 genes, which were previously detected in 
human, were also found in some primate species. In several locations in the FCN genes a consistent 
nucleotide is found within the primate species that differs from the human sequence (appendix 9.2). 
These locations may be ideal to search for variation in the human FCN genes and would be both 
time- and cost-saving when screening for new variations in the human FCN genes. Of particular 
interest are the nucleotides that alter the encoded amino acids in the protein, thus giving rise to non-
synonymous variations. If a nucleotide change, in accordance with the consistent primate 
nucleotide, had occurred in the human FCN genes, it would give rise to several non-synonymous 
variations. In FCN1, it involves the nucleotides in position +4764 giving rise to a His126Tyr 
variation and the nucleotide in position +6686 giving rise to an Asp227Gly variation. In FCN2, it 
involves the nucleotide in position +34 giving rise to an Ala12Ser or Ala12Pro variation, the 
nucleotide change in position +52 giving rise to a Ser18Thr variation and the nucleotide change in 
position +2528 giving rise to a Pro88Ser variation. Non-synonymous variations in the coding 
 53 
region may have impact on protein structure and function. Non-synonymous variations may also 
introduce stop codons or frame shifts that may lead to defective or truncated proteins. Furthermore, 
the post-translational modifications of the protein could be affected if a single amino acid is altered. 
Non-synonymous variations may also have a consequence on the three-dimensional structure of the 
protein or affect the non-covalent interactions and consequently distressing the protein stability or 
alter the binding to interacting molecules. Comparing the non-synonymous variations found in the 
human FCN genes with the primate FCN genes a striking similarity in the locations of the non-
synonymous variations is observed (figure 21). Most of the non-synonymous variations are 
clustered in the FBG domain in the FCN genes and may thus affect ficolins affinity or specificity of 
carbohydrate binding to microorganisms. During the evolution the FBG domain has co-evolved 
with microorganisms and modification of the FBG domain could give rise to a broad diversity 
against different microorganisms and due to positive selective forces different variations was 
established in the FBG domain. In order to clarify the molecular effect of these non-synonymous 
variations further work is required.  
 
… 
Figure 21: Location of non-synonymous variants in the FCN genes of human and the investigated primate 
species. Illustration of the exons and domain organisation of the FCN1, FCN2 and FCN3 genes. Black vertical lines 
above the illustrated genes separate exon regions. The genetic variations leading to amino acid changes are shown 
below the genes.  
 
 FCN1: In the human and the primate FCN1 gene, several non-synonymous variations were found 
in the collagen-like domain, which is not observed to the same degree for the FCN2 or FCN3 genes 
(figure 21). In the primate species the following non-synonymous variations were found in the 
collagen-like domain: chimpanzee Arg93Gln, rhesus macaque Ile68Val and Ile68Ala, baboon 
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Arg72Gly and common marmoset Gly103Arg. In the chimpanzee the non-synonymous variation 
Arg93Gln, has previous been detected as a common variation in the human African population with 
an allele frequency of 0.07 in the Mozambique population and an allele frequency of 0.09 in the 
population from Ghana. Furthermore, this non-synonymous variation was also detected in the 
Japanese population with a lower allele frequency of 0.01 [27]. Non-synonymous variation situated 
in the collagen-like domain may influence the interaction with the MASPs, which are responsible 
for activating the lectin pathway of the complement system. Whether these variations in the 
collagen-like domain affect the MASPs binding to Ficolin-1 remain to be elucidated. Nevertheless, 
these non-synonymous variations could also prevent the correct folding of the oligomers, causing 
protein instability, reduced protein concentration and/or reduced binding capacity towards ligands 
due to incomplete oligomerisation [27].  
 
In the signal peptide a novel non-synonymous variation Glu2Lys was found in the cynomolgus 
macaque that might affect the transport system and thus the secretion of the protein. In the FBG 
domain six new non-synonymous variations were found (figure 21) in the following primate 
species: orangutan (Thr249Met), rhesus macaque (Met162Val, Arg182Trp, Gly227Ser) and 
cynomolgus macaque (Thr133Pro and Leu141Pro). Non-synonymous variation situated in the FBG 
domain may affect the affinity and specificity of the carbohydrate binding towards microorganisms. 
To elucidate the functional effect of these variations further molecular investigations is needed. The 
crystal structure of the FBG domain of Ficolin-1 and it interaction with ligands has been 
investigated [43]. In the chimpanzee the residue Ser268 (Ser239 in Garlatti et al., 2007 since their 
nomenclature does not contain the leader peptide of 29 amino acids) is found as a Leu268. The 
Ser268 residue is involved in the Ca
2+
 coordination in Ficolin-1 and may be affected in the 
chimpanzee. Furthermore, the Gly250 (Gly221 in Garlatti et al., 2007) situated in the S1 binding 
site are found as an alanine residue in the orangutan, the rhesus macaque, the cynomolgus macaque 
and the baboon. This may change the binding pocket and thus interfere with the ligand binding. In 
Ficolin-2 the Gly250 (Gly221 in Garlatti et al., 2007) is replaced with the bulkier phenylalanine, 
which reduced the size of the binding pocket, thereby limiting its access to larger carbohydrate 
molecules such as NeuNAc [43]. 
 
In the gorilla, the initiating codon methionine (ATG) was found to be located in residue 8, with 
respect to the human sequence. Searching the NCBI database, no transcript variants of Ficolin-1 
has been described in the human. This transcript variant of the gorilla does not affect the reading 
frame and encode a total of 319 amino acids lacking 7 amino acids in the N-terminal region. 
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Whether the gorilla species also harbour transcripts starting from position +1 remains to be 
elucidated. 
 
Heterogeneity of the FCN1 gene was found between human and common marmoset, which for the 
common marmoset case entail a differentiated FCN1 gene thus affecting the Ficolin-1 molecule. 
Common marmoset homozygous for the marmoset reference analogue sequence, which carries an 
insert of 19 nucleotides, results in an altered amino acid composition in the N-terminal region of 
the molecule spanning from position +1504 to a premature stop codon at position +1514 thus given 
rise to a putative truncated form of Ficolin-1. This may lead to complete Ficolin-1 functional 
deficiency and thus give rise to a novel complement deficiency. Individuals heterozygous for the 
marmoset reference analogue sequence might have a lower Ficolin-1 concentration compared to 
individuals with the “normal” human reference analogue sequence as in the case seen for 
individuals heterozygous for the L117fs variation [10]. Moreover, the FBG domain of the common 
marmoset lacks several nucleotides compared to the human FGB domain, which results in an 
alteration of 15 amino acids in exon 8 and an altered amino acid composition spanning from 
position +7965 to a premature stop codon at position +8040 in exon 9. The functional effect of 
these differences in the FGB domain of the common marmoset Ficolin-1 molecule remains to be 
elucidated and so far no translation products of these variants have been described.  
 
FCN2: Ten novel non-synonymous variations, and one non-synonymous variation previous 
detected in human was found in the FCN2 gene in the following primate species: chimpanzee 
(Val149Met, Phe155Leu), orangutan (Arg103His, Thr161Ala), rhesus macaque (Gly72Arg, 
Val149Met, Ala185Thr, Glu217Lys, Ser253Asn, Met260Ile), cynomolgus macaque (Val149Met, 
Val227Ala) and common marmoset (Thr161Ala). The Ala185Thr variation detected in the rhesus 
macaque has previous been detected in the Japanese population with a frequency of 0.01. 
Interestingly, the non-synonymous variation Val149Met occurred in more than one primate species, 
namely in the chimpanzee, the rhesus macaque and the cynomolgus macaque. Additionally, the 
non-synonymous variation Thr161Ala or Ala161Thr occurred in the orangutan and common 
marmoset. The crystal structure of the FBG domain of the Ficolin-2 and its interactions with 
ligands has been described [44]. The Thr161 (Thr136 in Garlatti et al., 2007 since their 
nomenclature does not contain the leader peptide of 25 amino acids) is located in the S3 binding 
site and the amino acids are involved in the interaction with GalNAc, acetylcholine and curdlan. In 
theory, the variation Thr161Ala found in the orangutan and marmoset, which is an alanine in the 
rhesus macaque, the cynomolgus macaque and the baboon, may affect the interaction with ligands. 
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In Ficolin-2, Van der Waals contact is established between Phe114 and Gln164 (Phe89 and Gln139 
in Garlatti et al., 2007). In the baboon the amino acid arginine is located in this residue and may 
interfere with the inter protomer interfaces of Ficolin-2. Furthermore, the Asn253 (Asn228 in 
Garlatti et al., 2007) are involved in the Ca
2+
 coordination. In the common marmoset a histidine is 
found in this residue and this may affect the binding of Ca
2+
 and thereby affect the Ca
2+
 dependent 
ligand binding. Furthermore, two synonymous variations previously detected in human FCN2 gene 
were also detected in the rhesus macaque, baboon and common marmoset. The Asn177Asn 
variation, detected in Japanese population with an allele frequency of 0.429 [45] was also detected 
in the rhesus macaque. The His181His variation previously found in human samples from 
Argentina, Japan, Denmark and Ghana with an allele frequency of 0.19, 0.14, 0.03 and 0.01, 
respectively [27] were also found in the baboon and the common marmoset. 
 
Moreover, the human synonymous variation Gly54Gly, where a G nucleotide in position +1766 is 
exchanged for an A nucleotide, the A nucleotide is detected in the common marmoset but not in the 
rest of the investigated primate species which has a G nucleotide in this position. All these finding 
findings imply that Ficolin-2 may thus have an ancient origin and originate from a common 
ancestor. 
 
FCN3: An intact and highly conserved FCN3 gene was found in all the investigated primate 
species. Nevertheless, in mice and rats the FCN3 gene has been identified as a pseudogene, and it is 
reasonable to assume that the gene-inactivation has arisen after the branching of the rodent lineages 
[18]. As for the human gene, the primate FCN3 genes contained only few genetic variations in 
contrast to the FCN1 and FCN2 genes. Only six different variations were found, which were 
distributed between the gorilla (Gly218Ser) and in the cynomolgus macaque (Gly72Ser, 
Thr125Met, Asp235Gly, Gly251Ser, Ala256Gly). Why the FCN3 gene of the cynomolgus 
macaque was found to be more polymorphic than the rest of the investigated primates remains 
speculative.  
The synonymous variation Gly17Gly in exon 1 at position +51, where a G nucleotide is substituted 
by an A nucleotide, an A nucleotide was found for the rhesus macaque, the cynomolgus macaque 
and the baboon. The rest of the investigated primate species all had a G nucleotide located in this 
position. 
 
 
 
 57 
6.1.2 Serum analysis of the ficolins in different primate species 
It was not possible to collect serum samples from all the primate species that we obtained DNA 
samples from and furthermore we were not able to obtain several serum samples from the same 
primate species except for the chimpanzee. From the Copenhagen Zoo, we obtained serum samples 
from the following primate species: chimpanzee, gibbon, baboon, cotton top tamarin, golden-
headed lion tamarin, black and white ruffled lemur and black-handed spider monkey. All the assays 
performed on primate serum were optimised on the basis of analysis of human serum using anti-
human ficolin antibodies. However, most of the anti-human antibodies also reacted against primate 
ficolins. The FCN1 genes in the previously investigated primate species were intact and seemed to 
be functional. We were not able to analyse the oligomeric structure of primate Ficolin-1 for several 
reasons. Antibodies generated against human Ficolin-1 show some cross-reactivity with human 
Ficolin-2 due to the high degree of homology between Ficolin-1 and Ficolin-2. Secondly, Ficolin-1 
is found in very low concentrations (<0.1!g/ml) in human serum, which may also be the case for 
primates as well. One way to overcome these problems could be to deplete serum Ficolin-2, to 
avoid interference of Ficolin-2 due to the cross-reactivity of the Ficolin-1 antibodies, and 
subsequently immunoprecipitate Ficolin-1 in serum in order to get the Ficolin-1 concentration 
within the detection range. This method requires a lot of serum, which we were unable to obtain. 
Furthermore, at the laboratory a functional assay to measure the Ficolin-1 serum concentration in 
human or in chimpanzee has not yet been established. However, Ficolin-1 antibodies specific for 
Ficolin-1 are now being produced in our laboratory.   
 
Ficolin-2: SDS-PAGE subjected to western blot analysis showed that the primate species 
investigated had detectable Ficolin-2 protein in their sera and showed an identical banding pattern 
compared to the human Ficolin-2 protein, under both reduced and non-reduced conditions.  
 
The Ficolin-2 serum concentration was measured in serum samples from eight chimpanzees and 
was found to have a mean concentration of 3.7!g/ml. These findings are in agreement with the 
human Ficolin-2 serum concentration with a mean concentration of 5.0!g/ml [10, 15]. The slightly 
lower mean concentration of serum Ficolin-2 in chimpanzee could be due to the small number 
analysed or due to inter-individual variations. In human, the Ficolin-2 concentration is found to 
vary considerably among individuals and different polymorphisms in the promotor region have 
been described to decrease or increase the Ficolin-2 concentration [23]. Whether this phenomenon 
is also the case for the chimpanzees remains to be elucidated. In conclusion, all the primate species 
investigated expressed Ficolin-2 in serum that displayed the characteristic oligomeric pattern also 
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seen for human Ficolin-2. Furthermore, the Ficolin-2 expression in chimpanzees was found to have 
the same level as in humans.  
 
Ficolin-3: Until now, it is only in the human that Ficolin-3 has been purified and characterized. 
Serum samples from the primate species investigated were analysed on SDS-PAGE subjected to 
western blot. The above mentioned primate species all had detectable Ficolin-3, and this is the first 
time Ficolin-3 has been identified in other species than human. In order to visualize the chimpanzee 
Ficolin-3 we had to immunoprecipitate the sera prior to SDS-PAGE and western blot. For the 
baboon and cotton top tamarin a slightly lower molecule weight of the higher oligomeric structures 
were observed for Ficolin-3. Interestingly, under reduced conditions the monomer band had an 
identical molecular weight as observed for the monomers of the human and the other investigated 
primate species. The lower molecular weight observed for the higher oligomeric structures in the 
baboon and the cotton top tamarin may be a result of a different folding of the monomers into 
higher oligomeric structures or an altered three-dimensional structure. Looking at the baboon FCN3 
protein sequence, which we have sequenced (appendix 9.2.3), two residues differ in comparison 
with human and the investigated primate species: residue 87 where a histidine is found, which is 
located between the cys86-cys110 bridge (cys63-cys87 in Garlatti et al., 2007) and residue 242 
where an arginine is found. These two residues could give rise to slightly different oligomeric 
structures. In order to elucidate if these two residues are involved in the differentiated oligomeric 
structures, generation of recombinant human ficolin where the two residues has been mutated could 
clarify this assumption. In the rest of the primate species investigated, Ficolin-3 showed an 
identical banding pattern compared to the human Ficolin-3 protein under both reduced and non-
reduced conditions. Taken together, these results show that primate Ficolin-3 is a complex mixture 
of monomers and multimers, as seem in the case of human Ficolin-2.  
 
The Ficolin-3 concentration in serum was analysed in eight different chimpanzees and was found to 
be very low with a mean concentration of 1.1!g/ml compared to the mean concentration of 
25!g/ml in human [10]. The low Ficolin-3 concentration comes in agreement with the results 
observed by SDS-PAGE subjected to western blot, where it was necessary to concentrate 
chimpanzee Ficolin-3 prior to SDS-PAGE analysis. The low Ficolin-3 concentration observed in 
the chimpanzee could be a result of different circumstances. The use of human monoclonal Ficolin-
3 antibody may not have been able to recognize chimpanzee Ficolin-3 and as a result give rise to 
the observed low Ficolin-3 concentration. This explanation seems not to be the case, because the 
used monoclonal antibodies could recognize Ficolin-3 in lower primate species and moreover the 
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chimpanzee FCN3 gene is highly homologuos to the human FCN3 gene and looking at the protein 
sequence only three amino acids (residue 94, 190 and 225) differ in comparison with the human 
protein sequence (appendix 9.2.3). Moreover, as the only primate species chimpanzee Ficolin-3 
was immunoprecipitated prior to SDS-PAGE subjected to western blot and visualization with a 
polyclonal Ficolin-3 antibody, which recognize several epitopes on Ficolin-3. Giving these results, 
the low Ficolin-3 concentration measured in chimpanzees seems to be correct. The low Ficolin-3 
level observed in the chimpanzee could be a consequence of differences in the FCN3 promoter 
sequences or differences in the regulatory mechanisms compared to human, and this may affect the 
relative expression and protein translation of Ficolin-3; however further investigation is required to 
elucidate the reason. In conclusion, all the primate species investigated express Ficolin-3 in serum 
and display the characteristic oligomeric pattern seen in the case of human Ficolin-3. Furthermore, 
the Ficolin-3 expression in chimpanzees was found to be much lower than in humans. 
 
Moreover, we analysed if chimpanzee serum contains all the complement components needed to 
activate and generate MAC formation for all three complement pathways. We found that 
chimpanzee serum was able to generate MAC formation by the classical pathway, the alternative 
pathway and the MBL-pathway. The chimpanzee complement system may thus function in a 
similar fashion as in human. A weakness in this assay is that is does not analyse for the presence of 
the ficolins or their ability to activate the lectin pathway of the complement system. It has 
previously been shown that acBSA, but not BSA, can function as a ligand for Ficolin-3 and to a 
lesser degree for Ficolin-2. A plausible explanation for this could be the differences in serum 
concentrations of Ficolin-2 and Ficolin-3 [46]. We have just showed that chimpanzee serum 
contains both Ficolin-2 and Ficolin-3 and in order to investigate if the ficolins were able to activate 
the lectin pathway the C4-deposition was measured, which is an indirect method to detect the 
activation of the lectin pathway by Ficolin-3 [10].  No binding to BSA was observed and 
chimpanzee Ficolin-3 were able to perform C4-deposition in a similar fashion as observed for 
human. 
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6.2 Part II: Analyses of the human ficolin variants 
The human FCN1, FCN2 and FCN3 genes are highly polymorphic and genetic variations in the 
FCN genes may be associated with different diseases involving the function of the ficolin-mediated 
complement lectin pathway. Several non-synonymous variations have been found with large race-
related differences [27] that might influence serum concentration, structure and function of the 
ficolins. Functional experiments with recombinant protein variants, could clarify the molecular 
effect in greater detail. Full-length human FCN1, FCN2 or FCN3 cDNA were cloned into a pEDdC 
vector and subjected to site-directed mutagenesis and giving rise to 19 different constructs 
encoding the non-synonymous variations. The following variants were made and expressed in a 
CHO DG44 cell line: Ficolin-1 variants: rFicolin-1 wild-type, rG43D, rR93Q, rG303S and 
rW279stop Ficolin-2 variants: rFicolin-2 wild-type, rR103C, rK106R, rG117S, rT137M, rR147Q, 
rR157Q, rA185T, rT236M, rA258S and rA264fs Ficolin-3 variants: rFicolin-3 wild-type, rL12V, 
rL117fs, rT125A, rE166D and rV287A.  
6.2.1 Expression of rFicolin variants 
The success of expressing recombinant proteins is dependent on the expression system and the 
properties of the recombinant protein. Different expression levels were obtained for the generated 
rFicolin variants, but in general the rFicolin-2 variants gave a lower production yield compared to 
the rFicolin-1 and rFicolin-3 variants. Expression of recombinant proteins varies greatly among 
independent transformants. High-producer clones require lengthy selection, screening, and 
subsequent amplification procedures, which have not been conducted in these experiments. 
Variability in expression usually results from the number of genes incorporated and the site of 
chromosomal integration. Expression of recombinant protein was not successful in the case of the 
rW279stop, rA264fs and rL117fs variants. The W279stop variation terminates the protein prior to 
the glycosylation site in residue 305. The frame shift mutation A264fs results in alterations in the 
C-terminal end of the Ficolin-2 polypeptide with a reduction of 39 amino acid before termination 
compared to the wild-type. The L117fs variation alters the amino acid composition of the C-
terminal end of the protein spanning from amino acid position 117 to position 180, where the 
nonsense protein sequence is terminated as a result of a stop codon. In agreement with previous 
results, the L117fs variant was not expressed [10]. Additionally, homozygosity for these variants 
would most likely lead to complete Ficolin-1, Ficolin-2 or Ficolin-3 deficiency in vivo. 
Interestingly, a patient homozygous for the L117fs variant has been described and no Ficolin-3 
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expression was observed and this genetic variation is likely associated with chronic infections and 
disabling lung function [10]. 
6.2.2 The oligomeric pattern of the rficolin variants 
All the expressed rFicolin proteins displayed the characteristic oligomeric pattern seen for their 
respective ficolin type and are in complete agreement with previous findings [15]. Under non-
reduced condition, SDS-PAGE subjected to western blot showed that rFicolin-1, rFicolin-2 and 
rFicolin-3 variants were a mixture of monomers and multimers. The 12-mers forms of the rFicolin-
1 and rFicolin-2 variants were more dominant in their oligomeric profile compared to the 12-mers 
band of the rFicolin-3 variants. The rFicolin-3 variants are able to form even higher covalently 
linked oligomers corresponding to 18-mers and 24-mers. Under reduced condition, the oligomers of 
rFicolin-1, rFicolin-2 and rFicolin-3 variants were reduced to one single band.  
 
In Ficolin-2, it was predicted by computational analyses that the R103C variation might interfere 
with the disulfide patterns of the protein [27]. The variant may interfere with the different cysteines 
in the protein or interfere with the stabilizing disulfide bonds seen in the crystal structure of 
Ficolin-2 [44]. Furthermore, the variation may interfere with the cysteine located in the N-terminal 
region of the protein, which is critical for the oligomerization of the monomers. Analysing the 
rR103C variant on SDS-PAGE subjected to western blot a visible 12-mers band appears indicating 
that the monomers of the R103C are able to form covalently linked oligomers. Furthermore, it does 
not seem that the rR103C variant form even higher oligomeric forms that the other rFicolin-2 
variants. Taken these results together is does not seem that the R103C variation interfere with the 
cysteine located in the N-terminal region, but further analysis is required to verify this observation. 
6.2.3 Ligand binding 
It has previously been shown that acetylated compounds can function as ligands for the ficolins 
[46]. rFicolin-2 and rFicolin-3 have been observed to bind to acBSA, while no binding of rFicolin-
1 has been observed. Furthermore, rFicolin-3 appeared to bind with higher avidly to acBSA than 
rFicolin-2 [46]. We analysed the binding of the rFicolin-1, rFicolin-2 and rFicolin-3 variants 
towards acBSA and in agreement with the previous results, we found that the rFicolin-1 variants 
were not able to bind to acBSA, only a small binding to acBSA was observed for the rFicolin-2 
variants and the rFicolin-3 variants displayed a high avidity towards acBSA. Under the used assay 
conditions, we were not able to get a functional assay for rFicolin-1 and rFicolin-2 and further 
optimisation of a proper ligand-binding assay is needed. The exclusive binding of rFicolin-3 
towards acBSA may be explained by the differences in concentration and the avidity for acBSA of 
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the individual ficolins. Based on the binding results obtained for the rFicolin-3 variants, we found 
that the rL12V and rT125A variants had the same binding capacity towards acBSA as the rFicolin-
3 wild-type. A three-fold increase in binding capacity towards acBSA was observed for the rE166D 
variant, which was also found in the Japanese population with a frequency of 0.04 [27]. The 
increased binding capacity of the E166D variation might lead to an overactive protein and the 
consequence of this might be recognition and binding of host cells thus giving rise to an unwanted 
immune response. Alternatively, the variant may result in a gain-of-function in relation to 
immunity against certain microorganisms. In contrast, the V287A variation is located in the S1-
binding domain of the Ficolin-3 protein and theoretical affect the ligand binding capacity [27]. In 
fact, we found that the ligand binding capacity towards acBSA was lowered by this mutation. The 
V287A variation is found in the Mozambique population with a frequency of 0.01 [27]. Individuals 
homozygous for the V287A variations may have a non-functional FBG domain in the Ficolin-3 
molecule, which might be associated with chronic infections as observed for a Ficolin-3 deficient 
patient [10].   
 
In order obtain a functional assay for the rFicolin-2 variant, we analysed if curdlan could be utilized 
as target. Curdlan has previously been found to function as a ligand for Ficolin-2 [42]. 
Unfortunately, we were not able to repeat these findings for the rFicolin-2 variants, which might be 
explained by the low expression level obtained for the rFicolin-2 variants. 
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7. Conclusion and future perspectives  
 
7.1 Part I:  The primate ficolin 
We screened the exons and intron-exon boundaries of the FCN1, FCN2 and FCN3 genes for 
genetic variation in the following higher and lower primate species: chimpanzee, gorilla, orangutan, 
rhesus macaque, cynomolgus macaque, baboon and common marmoset. The exon organisation was 
very similar among the primates investigated and humans, indicating that all the investigated 
primates have functional FCN1, FCN2 and FCN3 genes that are closely related to the human 
FCN1, FCN2 and FCN3 genes, respectively. As in human, the FCN1, FCN2 and FCN3 genes of 
the primates were highly polymorphic and several novel inter-individual variations were found in 
all three FCN genes within each primate species. In FCN1 a novel transcript variant was found in 
the gorilla, encoding a polypeptide of 319 amino acids. Furthermore, heterogeneity of the FCN1 
gene was found between human and common marmoset, which for the common marmoset case 
entail a different FCN1 gene thus affecting the Ficolin-1 molecule. Interestingly, in FCN1 and 
FCN2 several variations were present in both human and some primate species and may thus have 
an ancient origin. The functional consequences of the non-synonymous variations found in the 
investigated primates remain to be elucidated. In vitro assays are time-consuming and as an 
alternative method computation variant analysis can serve as a guide to select the genetic variants 
that are most likely functionally relevant.  
 
Serum analysis of the following primate species: chimpanzee, gibbon, baboon, cotton top tamarin, 
golden-headed lion tamarin, black and white ruffled lemur and black-handed spider monkey 
showed the characteristic oligomeric structure of Ficolin-2 and Ficolin-3, respectively. This is the 
first time Ficolin-3 has been shown outside the human situation. In chimpanzees the Ficolin-2 and 
Ficolin-3 serum concentrations were found to be expressed at the same level or in very low levels 
compared to human, respectively. Moreover, chimpanzees complement system seems to function in 
a similar fashion as in human.  
 
Primates have functional FCN1, FCN2 and FCN3 genes that are highly homologue to the human 
FCN1, FCN2 and FCN3 genes. In contrast, rodents (mice and rats) that often are used as animal 
models have only two kinds of ficolins: Ficolin-! and Ficolin-" [18]. Primates would serve as a 
better animal model than rodents and in vivo studies of the primate ficolin could give a better 
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understanding of how the human ficolin function and give important insights into diseases 
involving the ficolin-mediated complement lectin pathway. 
7.2 Part II: Analyses of the rficolin variants  
We succeeded in expressing recombinant proteins of the non-synonymous variations found in the 
human FCN genes in a CHO DG44 cell line. As anticipated, the expression of the rW279stop, 
rA264fs and rL177fs was not possible. Different expression levels of the rFicolin-1, rFicolin-2 and 
rFicolin-3 variants were obtained. The expressed rFicolin-1, rFicolin-2 and rFicolin-3 variants 
displayed the characteristic oligomeric structure seen for Ficolin-1, Ficolin-2 or Ficolin-3, 
respectively.  
 
Under the used assay conditions we were not able to establish a functional binding assay for the 
rFicolin-1 or the rFicolin-2 variants. Other functional binding assays could be tried for instance 
rFicolin-1 or rFicolin-2 variants binding towards GlcNAc [20]. One of the main problems under the 
performance for the binding assays was the low concentration obtained for the recombinant 
proteins, especially seen for the rFicolin-2 variants. In order to obtain a higher expression level of 
the recombinant proteins in future studies, the CHO cells could be grown for a longer period before 
collecting the cell supernatant. Alternatively, the MTX concentration could be increased from 
200nM to 400-800nM in order to press the system to obtain a higher yield. Furthermore, the 
recombinant proteins could be designed to contain a His-tag, which then could be easily purified 
and concentrated from the cell supernatant using a Ni-NTA matrix. His-tagging the proteins might 
however be critical for the functionality of the recombinant products. In the laboratory we have 
expressed recombinant ficolin proteins (wild-type) that contain a carboxy-terminal 6 x His-tag in 
the C-terminal of the proteins [47], but it may be critical for the ligand binding through the C-
terminal FGB domain. His-tagging the N-terminal region is assumed to be critical for the 
oligmerization and thereby the overall structure of the protein.  
 
We were able to perform a functional assay for the rFicolin-3 variants and found a three-fold 
increase in binding capacity for the rE166D variant and furthermore that the binding capacity for 
the rV287A variant was almost totally abolished towards acBSA. With regard to these findings it 
could be interesting to investigate the ability of the rE166D and rV287A variants to activate the 
lectin pathway of the complement system and investigate if there is any association with the 
variants and susceptibility to infections and inflammatory diseases in human. 
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9.3 Protocols 
 
Protocol 1: Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction is a simple method to synthesise a large number of any given 
DNA sequence flanked by two primers.  
 
1. PCR stock solution:     4600 µl sterile H2O 
      600 µl 10xdNTP mix (2µM) 
       600 µl MgCl2 (50mM) 
    2000 µl 10xPCR Buffer 
      200 µl Cresol read 
    1000 µl Glycerol (99%) 
 
2. Primer Mix:  10 µl Forward Primer (10 µM) 
    10 µl Reverse Primer (10 µM) 
    80 µl sterile H2O 
 
3. PCR reaction, 1 reaction: 5 µl PCR stock solution 
    5 µl Primer Mix (1µM) 
0.4 µl genomic DNA  
0.05 µl Taq DNA Polymerase (5 units/µl) 
         
For more than one reaction make a stock solution by multiplying the volumes with the 
number of reactions. To ensure enough stock, increase the total amount of each reagent 
by 10%. 
 
4. Cycling parameters: segment 1: 92°C  2 minutes 
segment 2: 94°C  30 seconds  30 cycles of 
segment 2: 62°C  30 seconds   segment 2 
segment 2: 72°C  60 seconds   
    segment 3: 72°C  5 minutes 
 
5. Electrophorese: load 5 µl PCR product on an agarose gel (refer to protocol 2) 
 
Optimizing the PCR reaction: When new primers are used PCR condition must be 
optimise by first varying the primer concentration (0.25-1µM) and annealing 
temperature. If the reaction isn’t optimized consider other parameters such as annealing 
time, MgCl2 concentration, polymerase or DNA template.   
 
Materials: 
! Ultrapure dNTP set (Amersham Pharmacia, 
27-2035-03) 
! 50mM MgCl2  (P/N Y02016, Invitrogen) 
! 10xPCR Rxn Buffer (-MgCl2) (P/N Y02028, 
Invitrogen) 
! Glycerol (G9012, Sigma) 
! DNA primer (DNA Technology) 
! Platinum Taq Polymerase 5units/µl (10966-
034, Invitrogen) 
! 0.2ml thin wall tubes (Star lab, I14 02-2908)  
! Mastercycler epgradient (Eppendorf) 
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Protocol 2: Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis is a simple method for separating, identifying and purifying 
DNA fragments. 
 
Preparation of 2% agarose gel: 
1. Weigh 6 g agarose and add 300 ml 1xTEA buffer. 
2. Melt the agarose in a microwave oven for 5 minutes at max effect. 
3. Stir the melted agarose for 30 minutes or until it reaches ( 55(C and pour the melted 
agarose onto the gel platform and then insert the gel combs. Important avoid bubble 
formation. 
4. After the gel has hardened (>30 minutes), remove the combs and open the gel 
platform. Place the gel in a tank containing 1xTEA buffer with 0.25 mg/L ethidium 
bromide (EtBr). Leave the gel in the buffer for staining >30 minutes before use. 
5. The gel can be stored in TEA/EtBr buffer at room temperature for one month.  
 
Loading and running the gel: 
1. Cut out the desired number of wells from the standard gel with a sharp scalpel. 
2. Place the gel in the electrophoresis tank. The electrophoresis buffer (1xTEA buffer 
with 0.25mg/L EtBr) must cover the gel. 
3. Load the DNA samples and an appropriated DNA molecular weight marker on the 
gel. 
4. The gel is run at a voltage of 150V, a current limit of 400mA and the time interval 
desired. A 500bp fragment migrates to the middle of a 2% agarose gel in 20 minutes.  
5. Visualize the DNA by placing the gel in the UV illumination (320 nm) and 
photograph the gel. 
  
Materials: 
! SeaKem LE Agarose (Lonza, 5005) 
! 10x TEA (Ampliqon, AMPQ85800.1000) 
! Etidium Bromide Solution (Sigma, E-8751) 
! DNA Molecular Weight Marker V, 8-587 bp (Roche, 821 705) 
! Gel electrophoresis apparatus (BIO-RAD, Sub-Cell Model 192) 
! Gel casting platform with gel combs (BIO-RAD, 6x24 wells) 
! Electrophoresis Power Supply EPS-301 (Amersham Biosciences) 
!  
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Protocol 3: BigDye terminator cycle DNA sequencing 
Sequencing is a method to obtain the DNA sequence of a defined part of a DNA 
sequence. 
 
The following procedure is for one reaction only. For more than one reaction make a 
stock solution by multiplying the volumes with the number of reactions. To ensure 
enough stock, increase the total amount of each reagent by 10%. 
 
1. PCR Sequence Mix: 0.8 µl T7-primer*bio 
12 µl Big Dye Terminator 
2.0 µl sterile H2O  
1.0 µl PCR-product 
 
2. Cycling parameters: 96°C 20 seconds 
50°C 15 seconds  30 cycles 
60°C 1 minutes  
 
3. Sequence Mix:  45 µl 2xBW 
    45 µl Sterile H2O 
    3 µl Streptavidin- Sepharose -beads 
 
Preparing the samples for sequencing: 
1. Add 93 µl of the sequence mix to the PCR-product and incubate shaking for 5 
minutes. 
2. Apply vacuum to the pyrosequencing machine and aspirate the samples with the 
Vacuum Prep Tool.  
3. Still with the vacuum on, wash the beads by holding the Vacuum Prep Tool 5 seconds 
in 5 mmol/l NaOH. 
4. Subsequently wash the beads with 70% EtOH as describe in step 3. 
5. Hold the Vacuum Prep Tool over a 96-well PCR plate containing 15 µl formamid and 
release the vacuum.    
6. Centrifugate the PCR plate for 30 seconds at 1000 g.    
7. Analyzed the plate at an ABI Prism 3130xl Genetic Analyser.  
 
Preparing the 2xBW buffer:  500 µl Tris-HCL, 1 mol/l, pH 7,5 
     100 µl EDTA, 0,5 mol/l 
     33 ml NaCl, 3 mol/l 
     50 ml sterile H2O 
Materials: 
! Streptavidin Sepharose High Performance (GE Healthcare, 17-5113-01,) 
! Formamid deionised (Amresco, 0606-100ml) 
! Abgene PCR Plates (AB-0600, Thermo Scientific) 
! Axymat (VWR, 521-01-701) 
! Biotinylated T7-primer (5’-TA ATA CGA CTC ACT-3’) (DNA Technology) 
! Big Dye Terminator V.3.1 Cycle (AB, 4336911) 
! Sequence-machine: 3130xl (ABI Prism, Genetic Analyzer)  
! Pyrosequence machine and Vacuum Prep Tool (Bio-Tage) 
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Protocol 4: QuikChange Lightning Site-Directed Mutagenesis 
 
QuikChange Lightning Site-Directed Mutagenesis is a rapid, efficient and accurate 
method to generate mutant plasmids.  
 
1. PCR reaction:  5 µl 10x reaction buffer 
Add the reagent in the  X µl (10-100 ng) dsDNA template 
described order.  X µl (125 ng) Forward primer 
X µl (125 ng) Reverse primer 
1 µl dNTP mix 
1.5 µl QuickSolution reagent 
X µl to bring the final reaction volume to 50 µl by adding        
deionised H2O 
   1 µl of QuikChange Lightning Enzyme 
 
2. Cycling parameters: segment 1: 95°C 2 minutes 
    segment 2: 95°C 20 seconds  18 cycles of  
    segment 2: 60°C 10 seconds  segment 2 
    segment 2: 68°C 30 seconds/kb of plasmid length 
    segment 3: 68 °C 5 minutes 
 
3. Dpn I Digestion:  
3.1. Add 2 µl Dpn I restriction enzyme directly to each reaction. 
3.2. Mix each reaction by pipetting up and down several times. 
3.3. Briefly spin down the reaction. 
3.4. Immediately incubate at 37°C for 5 minutes. 
 
4. Transformation protocol: 
4.1. Gently thaw the XL10-Gold ultracompetent cells on ice.  
4.2. Aliquot 45 µl of the XL10-Gold ultracompetent cells in to a prechilled 14-ml BD 
Falcon polypropylene round-bottom tube for each reaction. 
4.3. Add 2 µl !-Mercaptoethanol mix to the cells. Swirl and incubate it on ice for 2 
minutes 
4.4.  For each reaction transfer 2 µl of the Dpn I treated DNA (point 3.4) to a cell-
tube. Gently swirl to mix and incubate it on ice for 30 minutes. 
4.5. Preheat the NZY
+
 broth to 42°C for use in step 4.8. 
4.6. Heat-pulse the tubes with 42°C for 30 seconds. Do not exceed 42°C.  
4.7. Immediately incubate the tubes on ice for 2 minutes. 
4.8. Add 0.5 preheated (42°C) NZY+ broth to each tube and then incubate the tubes 
shaking (225-250 rpm) at 37°C for 1 hour. 
4.9. Plate 10-250 µl of each transformation reaction on agar plates containing the 
appropriate antibiotic for the plasmid vector.  
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5. Preparation of media and reagents: 
 
LB Ager    NZY
+
 Broth 
10 g NaCl    10 g NZ amine  
10 g tryptone    5 g yeast extract 
5 g yeast extract   5 g NaCl 
20g agar    Add deionised H2O to a  
Add deionised H2O to a   final volume of 1 liter 
final volume of 1 liter   Adjust pH to 7.5 using NaOH 
Adjust pH to 7.0 with NaOH  Autoclave 
Autoclave    Add 12.5 ml 1M MgCl2 
Pour into Petri dishes    Add 12.5 ml 1M MgSO4 
     Add 10 ml 2M glucose 
For selective LB-plates add: 
Ampicillin/carbenicillin 50!g/ml 
IPTG 0.5 !M 
X-gal 80!g/ml 
Tetracycline 15!g/ml 
 
Materials: 
! QuikChange Lightning Site-Directed Mutagenesis kit (Stratagene, 210519) 
! DNA primers (DNA Technology) 
! Isopropyl-1-thio-!-D-galactopyranoseside (IPTG) 
! 5-Bromo-4-chloro-3-indolyl-!-D-galactopyranoseside (X-gal) 
! 14-ml BD Falcon polypropylene round-bottom tubes 
! Petri dishes (Nunc, 11262) 
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Protocol 5: Plasmid Purification with Quantum Prep Plasmid Miniprep Kit.  
 
The Quantum Prep Plasmid Miniprep Kit is a method to rapid purification of high-yield 
plasmid DNA from 1-4 ml liquid culture. The purified plasmid can directly be used for 
sequencing and cell transfection. 
 
Important notes before starting: 
! Prepare the Wash Buffer by adding 63 ml 96% ethanol to the Wash Buffer before 
use. 
! All centrifugation steps are performed at maximum speed (12-14,000 x g). 
 
1. Make and overnight culture by picking a single colony and inoculate in 10 ml LB 
medium containing the appropriate antibiotic (50 µg/ml carbenicillin and 15 µg/ml 
tetracyline). Incubate at 37°C with vigorous shaking (300 rpm). 
2. Mix 0.5 ml overnight culture with 0.5 ml glycerol-solution and store it at -80°C.  
3. Transfer 1-2 ml of an overnight culture of plasmid-containing cells to a 
microcentrifuge tube. Centrifuge the tube for 30 seconds and remove the supernatant. 
4. Add 200 µl of the Cell Resuspension Solution and mix until the cell pellet is 
completely resuspended. 
5. Add 250 µl of the Cell Lysis Solution and gently mix by inverting the tube 10 times. 
6. Centrifugate of 5 minutes 
7. While waiting for the centrifugation step at step 5 prepare following: 
I. For each sample insert a Spin Filter into the provided 2-ml tube 
II. Mix the Quantum Prep matrix by shaking and inversion of the bottle until it is 
completely suspended. 
8. Transfer the supernatant from step 5 to a Spin Filter, then add 200 µl Quantum Prep 
matrix and mix by pipetting up and down. For more than one sample transfer the 
supernatant first, and then add matrix and mix. 
9. Centrifugate for 30 seconds.  
10. Discard the filtrate and reuse the same Spin Filter and 2-ml tube for each sample. Add 
500 µl Wash Buffer to the Spin Filter and centrifuge for 30 seconds. 
11. Discard the filtrate and reuse the same Spin Filter and 2-ml tube for each sample. Add 
500 µl Wash Buffer to the Spin Filter and centrifuge for 2 minutes. 
12. Take the Spin Filter and place it in a new 1.5 ml microcentrifuge tube. Discard the old 
microcentrifuge tube with Wash Buffer. 
13. Elute the DNA by adding 100 µl deionised H2O or TE and centrifuge for 1 minute. 
14. Discard the Spin Filter and store the eluted DNA at –20°C. 
 
Materials: 
Quantum Prep Plasmid Miniprep Kit (BIO-RAD, 732-6100) 
LB-media containing 50 µg/ml carbenicillin and 15 µg/ml tetracyline. 
Glycerol-solution: 65% Glycerol (Sigma, G-9012), 0.1M MgSO4 (Merck, 886.1000) and 
0.025M Tris-HCL, pH 7.5 (Bie & Berntsen, Lab85200) 
 
 
 
 93 
Protocol 6: Plasmid Purification with Endofree Plamid Maxi prep 
 
The QIAGEN EndoFree Plasmid Kit is designed for purification of up to 500 µg 
endotoxin-free high copy plasmid DNA. 
 
Important notes before starting: 
! Use endotoxin-free plastic tip and tubes for elution and subsequent steps (from 
step 15). 
! Add the provided RNase A solution to Buffer P1 before use. 
! Prepare endotoxin-free 70% ethanol by using the endoxin-free water supplied. 
! Check Buffer P2 for SDS precipitation. SDS precipitation can be dissolve by 
warning it to 37°C. 
! Pre-chill Buffer P3 to 4°C. 
 
1. Make a starter culture by picking a single colony and inoculate in 2-5 ml LB medium 
containing the appropriate antibiotic (50 µg/ml carbenicillin and 15 µg/ml 
tetracyline).  Incubate approx. 8 h at 37°C with vigorous shaking (300 rpm). 
2. Dilate the starter culture 1/500 or 1/1000 into selective LB medium. Incubate at 37°C 
for 12-16 h with vigorous shaking (300 rpm). 
I. High-copy plasmids: 100 ml medium with 100-200 µl starter culture 
II. Low-copy plasmids: 250 ml medium with 250-500 µl starter culture 
3. Harvest the bacterial cells by centrifugation at 6.000 x g for 15 minutes at 4°C.  
4. Remove the supernatant. The cell pellets can be frozen at -20°C if you wish to stop 
the protocol and continue later. 
5. Resuspend the bacterial pellet in 10 ml Buffer P1. 
6. Add 10 ml Buffer P2 and mix by vigorously inverting the tube 4-6 times. Incubate at 
room temperature (15-25°C) for 5 minutes. 
7. While waiting for the incubation step in step 6 prepare the QIAfilter Cartridge. Screw 
the cap onto the outlet nozzle of the QIAfilter Maxi Cartridge and place the in a 
convenient tube. 
8. Add 10 ml chilled Buffer P3 to the lysate and mix by vigorously inverting the tube 4-
6 times. 
9. Pour the lysate into the barrel of the QIAfilter Cartridge. Incubate at room 
temperature (15-25°C) for 10 minutes. Important do not insert the plunger. 
10. Remove the cap from the QIAfilter Cartridge outlet nozzle. Insert the plunger and 
filter the cell lysate into a 50 ml tube. 
11. Add 2.5 ml Buffer ER to the filtered lysate and mix by inverting the tube 10 times. 
Incubate on ice for 30 minutes. 
12. While waiting for the incubation step in step 11 equilibrate the QIAGEN-tip 500 by 
adding 10 ml Buffer QBT. Allow the column to empty by gravity flow. 
13. Apply the filtered lysate from step 11 to the equilibrated QIAGEN-tip and allow it to 
enter the resin by gravity flow. 
14. Wash the QIAGEN-tip with 2 x 30 ml Buffer QC. Allow the column to empty by 
gravity flow. 
15. Place the QIAGEN-tip in a new 50 ml tube and elute DNA with 15 ml Buffer QN. 
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16. Precipitate DNA by adding 10.5 ml room-temperature isopropanol to the eluted 
DNA. Mix and centrifuge immediately at 15.000 x g for 30 minutes at 4°C. 
Alternative centrifuge 5.000 x g for 60 minutes at 4°C. 
17. Carefully decant the supernatant and wash DNA pellet with 5 ml of endotoxin-free 
room temperature 70% ethanol and centrifuge at 15.000 x g for 10 minutes at 4°C. 
Alternative centrifuge at 5.000 x g for 60 minutes at 4°C. 
18. Carefully decant the supernatant without disturbing the pellet 
19. Air-dry the pellet for 5-10 minutes and redissolve the DNA in a suitable volume of 
endotoxin-free Buffer TE. 
20. Determinate the DNA concentration by spectrophotometry at 260 nm. 
 
Materials: 
QIAGEN Plasmid Maxi Kit (Qiagen, 12162) 
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Protocol 7: Maintenance of CHO-DG44 (dhfr-) cells 
 
Culturing and maintenance of CHO-cells for transfection of recombinant proteins. 
 
Important notes before starting 
Gloves are always worn to protect hands and the cells from contamination. A laboratory 
coat should be worn to protect clothes from contamination. Doors of the culture room 
should remain closed to decrease the amount of air born contaminants entering the 
incubators and the room. Equipment (incubators, centrifuges, microscopes, tabletops, 
etc.) should be cleaned routinely with soap and 70% ethanol to help maintain a sterile 
work environment. 
 
Other relevant information 
Chinese Hamster Ovary (CHO) cells (CHO-DG44, Lawrence Chasin, Columbia 
University, New
 
York), transfected with recombinant Ficolins.  
Morphology and growth: grown as monolayer, fibroblast-like and epithelian-like.  
Spilt culture: 2 times per week (1:10-1:20).  
Incubation conditions: 37°C in humidified atmosphere containing 5% CO2.  
 
Thawing frozen cells 
1. Get the cells from the nitrogen containers in the basement and thaw the cells by 
rubbing it against your gloved-hands. 
2. Once the cells starts thawing dump them into a 25cm2 flask and add 10 ml culture 
medium. 
3. Grow the cells for 2 hour in horizontal position in the incubator and replace the 
medium with 10 ml fresh medium. 
4. Grow the cells overnight in the incubator and check the cells on the microscope each 
day. Once the cells reach confluency, they can be splitted. 
 
Splitting the cells 
1. Wash the cells twice with sterile PBS buffer. To do this, remove the media from the 
plate and save it at -20ºC for purification of Ficolin. Add 2-4 ml PBS and swirl the 
plate to wash the cells. Remove the PBS and add another 2-4 ml of PBS, swirl and 
remove. 
2. Add 0.5-1 ml Trypsin solution to the cells, making sure that all the cells on the plate 
are covered with this solution, and incubate for about 3 min or until all the cells have 
detached from the plate.  
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3. Add 10 ml of culture media to the cells, then pipet up and down several times. 
4. For splitting the cells 1:10, transfer 1 ml to a new culture plate and add 9 ml culture 
medium. 
5. Place the plate into the incubator and check cells every other day for confluency, 
changing the media on those days.  
 
Freezing the CHO cells 
This protocol gives 5x 1.5 ml tubes of cells. It is essential to keep the time the cells are 
exposed to the DMSO in the freezing medium at a minimum. Prepare the freezing tubes 
with labels and make sure that a freezing box is available. The cells must be in 
logarithmic phase of growth. 
1. Perform the same procedure as when splitting the cells (1-3).  
2. Centrifuge the cells for 5 min at 1500 RPM.  
3. Remove the medium and add 5 ml of Cell Freeze Medium and pipet up and down. 
4. Pipette 1 ml into each of the 5 cryotubes. DMSO is toxic to cells, therefore begin 
freezing immediately after transferring the cells to cryotubes. Load the cryotubes into 
the freezing box and put it in the -80°C freezer overnight. 
5. Transfer the cells to a permanent storage container. Samples should be moved 
quickly to prevent thawing or warming and sample deterioration.  
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Protocol 8: Lipofectamine Transfection 
 
Important notes before starting: Gloves are always worn to protect hands and the cells 
from contamination. Equipment (incubators, centrifuges, microscopes, tabletops, etc.) 
should be cleaned routinely with soap and 70% ethanol to help maintain a sterile work 
environment. 
 
Day -1: The CHO (dhfr-) cells are grown to be 90-95% confluente at day 0. 
Day 0: Trypsinize the cells with 0.05% trypsin in PBS and seed 1.4 x 10
6
 cells in 6 cm 
Petri dishes. Do not use antibiotics in transfection medium and avoid using antibiotics 
even when plating cells for transfection. 
Day 1: Transfect cells: 
1. 14 !g DNA + 0.2 !g pSVneo in 500 !l OPTI-MEM medium (mix gently). 
40 !l Lipofectamine 2000 in 500 !l OPTI-MEM medium (mix gently, incubate 
for 5 min at RT). 
2. After 5 min incubation, the DNA and the Lipofectamine are mixed gently and 
incubated for 20 min at RT. Then add the 1 ml DNA-Lipofectamine complexes to 
each well. 
3. Wait 48-72h following transfection before beginning selection. This allows the 
cells to express adequate amounts of the resistance enzyme to protect them when 
selection begins. 
Day 2: Investigate the cells in microscope and replace the media. Move the cells to T25 
flask. 
Day 3: Start the G418 selection and omit HT media supplement.  
Day 7-14: When colonies are formed and the cells are treated with trypsin and fresh 
media is added. Move cells to larger flasks when dense. 
Day 10-14: When G418 resistant clones are obtained, selection and gene amplification 
with MTX is initiated by cultivation cells in IMDM containing 50 nM MTX. After cells 
have regained normal growth rate and morphology, increase the MTX concentration to 
200 nM (no significant amplification of MBL into medium was seen at levels of MTX 
above 200 nM). 
 
Be sure to freeze samples whenever possible to avoid having going back to the beginning 
in the event of contamination.  
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Cell media for Lipofectamine transfection: 
 
Days until -2: Untransfected cells are grown in IMDM-A: 
500 ml  Iscove´s Modified Dulbecco´s Medium (IMDM)-medium 
10 ml  HT media supplement (x50), add 10 ml medium to one vial  x1 
5 ml  L-glutamin (200mM)       2 mM 
5 ml  Penicillin/Streptomycin (10.000U/10mg)        0.1 mg/ml 
50 ml Sterile filtrated dFCS (dialyzed fetal calf serum),    10% 
heat-inactivated 30 min. at 56°C 
 
Day -1 and 0: Transfection is performed in IMDM-B: 
500 ml  Iscove´s Modified Dulbecco´s Medium (IMDM)-medium 
10 ml  HT media supplement (x50), add 10 ml medium to one vial  x1 
5 ml  L-glutamin (200mM)       2 mM 
50 ml  Sterile filtrated dFCS (dialyzed fetal calf serum),    10% 
  heat-inactivated 30 min. at 56°C 
 
Day  1-2: Transfected cells are grown in IMDM-A: 
500 ml  Iscove´s Modified Dulbecco´s Medium (IMDM)-medium 
10 ml  HT media supplement (x50), add 10 ml medium to one vial  x1 
5 ml  L-glutamin (200mM)       2 mM 
5 ml  Penicillin/Streptomycin (10.000U/10mg)        0.1 mg/ml 
50 ml Sterile filtrated dFCS (dialyzed fetal calf serum),    10% 
heat-inactivated 30 min. at 56°C 
 
Day 3: Transfected cells are grown in IMDM-C: 
500 ml  Iscove´s Modified Dulbecco´s Medium (IMDM)-medium 
5 ml  L-glutamin (200mM)      2 mM 
5 ml  Penicillin/Streptomycin (10.000U/10mg)   0.1 mg/ml 
50 ml Sterile filtrated dFCS (dialyzed fetal calf serum),   10% 
heat-inactivated 30 min. at 56°C 
5 ml  G418 (50 mg/ml), 5g G418 in 100 ml sterile H2O  0.5 mg/ml 
 
Day ~ 10-14: G418 resistant transfected cells are grown in IMDM-D: 
500 ml  Iscove´s Modified Dulbecco´s Medium (IMDM)-medium 
5 ml  L-glutamin (200mM)      2 mM 
5 ml  Penicillin/Streptomycin (10.000U/10mg)   0.1 mg/ml 
50 ml Sterile filtrated FCS, heat-inactivated 30 min. at 56°C 10% 
5 ml  G418 (50 mg/ml), 5g G418 in 100 ml sterile H2O  0.5 mg/ml 
5 !l Methotrexate MTX (5mM)     50 nM 
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Materials: 
• Iscove´s Modified Dulbecco´s Medium, IMDM-medium (Sigma I3390) 
• 2mM L-glutamine (Sigma, G7513)  
• 10.000U/10mg Penicillin/Streptomycin (Sigma P7539) 
• FCS (fetal calf serum) (Gibco, 10270-106) 
• HT media supplement (Sigma H0137) 
• Trypsin (Invitrogen 25200-072) 
• Culture Flasks (CM-lab) 
 
Buffers and media: 
• Sterile filtrated phosphate buffered saline (PBS) buffer 
50 ml 20xPBS buffer 
950 ml H2O 
• Freezing solution 
25 ml IMDM-medium 
15 ml sterile filtrated FCS, heat-inactivated 30 min. at 56ºC 
10 ml DMSO (from MLC-lab) 
• Culture Medium (Mix inside the hood, store the mixed medium at 4ºC for 1 month) 
 500 ml Iscove´s Modified Dulbecco´s Medium (IMDM)-medium 
 5 ml L-glutamin (200mM) 
 5 ml Penicillin/Streptomycin (10.000U/10mg) 
 10 ml HT media supplement (add 10 ml medium to one vial) 
 50 ml sterile filtrated FCS (fetal calf serum), heat-inactivated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 100 
Protocol 9: Immunoprecipitation 
 
This protocol is use to concentrate a specific protein with help from magnetic beads and 
antibodies.  
  
1. Use 15 µl magnetic dynabeads conjugated with anti-mouse IgG antibodies 
(Dynabeads Pan Mouse, 110.41, Invitrogen) per sample.  
2. Wash the beads twice in 200 µl PBS-T; add the PBS-T and vortex when place 
it in the magnetic rag and discard the supernatant. 
3. Add the catching antibody for 1h at RT, shaking 
4. Wash the beads as in step 2 
5. Resolve the beads in PBS-T 
6. Add serum or cell supernatant diluted in PBS-T to the beads and incubate for 
1 h at RT, shaking. Vortex 3-4 times in that period 
7. Wash the beads as in step 2 
8. Add LDS-sample buffer diluted 1:2 in PBS-T. Samples are now ready for 
SDS-page 
 
Materials: 
!  Dynabeads Pan Mouse IgG (Invitrogen, 110.41) 
!  Magnetic rag (Dynal, MPC-S or MPC-9600) 
! Tween (20X) (Merck, S4321284) 
! PBS (20X) (Bie&Berntsen, Lab7963.1000) 
! NuPAGE LDS Sample Buffer (4X) (Invitrogen, NP0007) 
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Protocol 10: SDS page and Western Immuno Blotting 
 
Western blots are used to detect specific proteins in a sample using gel electrophoresis. 
The proteins are transferred from the gel to a membrane and visualized by specific 
antibodies.  
 
Prepare samples for SDS-PAGE: 
1. Mix the samples as follows and mix thoroughly: 
Reagent    Non-reduced Sample  Reduced Sample 
Sample        x µl       x µl 
NuPAGE LDS Sample Buffer (4X)  2.5 µl    2.5 µl 
NuPAGE Reducing Agent (10X)    - -     1.0 µl 
PBS-buffer             to 7.5 µl           to 6.5 µl 
Total volume                 10 µl    10 µl 
 
2. Heat the samples at 70˚C for 10 minutes. 
 
Preparing 1X TRIS-Acetate Running Buffer for Tris-Acetate Gels: 
NuPAGE Tris-Acetate SDS Running Buffer (20X)   40 ml 
Deionised H2O                760 ml  
Total volume                            800 ml 
 
Preparing 1X MES Running Buffer for Bis-Tris Gels: 
NuPAGE MES SDS Running Buffer (20X)    40 ml 
Deionised H2O                760 ml  
Total volume                            800 ml 
 
Electrophoresis of NuPAGE Gels: 
Important wear protective gloves under the whole procedure to avoid exposure to irritants 
and to prevent contamination of the gels and membranes. 
1. Take the NuPAGE gel out of the pouch. 
2. Rinse the gel-cassette with deionised water and peel of the tape from the bottom of 
the gel-cassette and remove the comb. 
3. Place the two gels in the Mini-Cell such that the notched “well” side of the cassette 
faced inwards toward the Buffer Core. Seat the gels on the bottom of the Mini-Cell 
and lock into place with the Gel Tension Wedge. Note: If using only one gel, use the 
plastic Buffer Dam in replacement for the second gel cassette. 
4. Fill the Upper Buffer Chamber with 1X NuPAGE Running Buffer and check for 
tightness of seal. If you detect a leak from the Upper Buffer Chamber to the Lower 
Buffer Chamber, discard the buffer, reseal the chamber, and refill. 
5. Fill up the Lower Chamber of the XCell SureLock
TM
 Mini-Cell with 1XNuPAGE 
Running Buffer. The buffer level must exceed the level of the wells. 
6. Load the samples and a protein standard marker onto the gel.  
Load 10-15 µl for 10-well gels 
Load 5-10 µl for 15-well gels 
7. Run the gels at 150V and 300mA for 1-1 ! hour 
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Western Transfer Protocol 
Important: Wear protective gloves under the whole procedure to avoid exposure to 
irritants and to prevent contamination of the gels and membranes. 
 
Preparing 1X NuPAGE Transfer Buffer  1 Gel  2 Gels 
NuPAGE Transfer Buffer (20X)   25 ml    25 ml 
96% Ethanol      50 ml  100 ml 
Deionised H2O               425 ml  375 ml 
Total volume               500 ml  500 ml 
 
1. Transfer the 1X NuPAGE Transfer Buffer to a container and soak 5 pads. 
2. Cut filter paper to the dimensions of the gel 
3. Separate each of the three bonded sides of the gel cassette by inserting the Gel Knife 
into the gab between the cassette’s two plates and separate the plates. 
4. Remove and discard the top plate allowing the gel to remain on the bottom plate. 
5. Remove the wells and the “foot” off the gel with the Gel Knife. 
6. Assemble the XCell II Blot Module as follows: 
 
 
 
  Assemble with one gel        Assemble with 2 gels 
 
7. Position the Blot Module in the Mini-Cell and fill the blot module with 1XNuPAGE 
Transfer Buffer until the gel/membrane/pads assembly is covered in buffer 
8. Fill the outer buffer chamber with deionized water  
9. Run the blot at 30V and 300mA for 1 hour. 
10. Transfer the membrane to a container containing 5% drymilk (2.5g in 50 ml PBS-T) 
and block for 1 hour. 
11. Briefly rinse the membrane twice in PBS-T. 
12. Wash the membrane by suspending it in PBS-T and agitating for >5 minutes, repeat 
at least 2-3 times. Increasing the wash buffer volume and/or the number of washes 
may help reduce background. 
13. Add the appropriate primary antibody (1/2000 or 10-200ng/ml) and incubate for 1 
hour with shaking or overnight at 2-8°C. 
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14.  Repeat the washing step in step 12 
15.  Add the appropriate secondary HRP-conjugate antibody dilution (1/5000 or 2-
10ng/ml) and incubate for 1 hour with shaking or overnight at 2-8°C. 
16. Briefly rinse the membrane twice in PBS-T. Wash the membrane by suspending it in 
PBS-T and agitating for (15 minutes. Replace PBS-T at least 4-5 times. Increasing the 
wash buffer volume and/or the number of washes may help reduce background. 
17. Prepare Working Solution by mixing equal parts of the Stable Peroxide Solution and 
Luminol/Enhancer Solution from the SuperSignal West Femto Maximum Sensitivity 
Substrate (2 ml x 2 ml). Exposure to the sun or any other intense light can harm the 
Working Solution. 
18. Place the membrane on a plastic membrane and incubate with the Working Solution 
for 1-2 minutes. 
19. Remove the Working Solution from the membrane with paper tissue and place a 
plastic wrap on the top of the blot. 
20. Place the protected membrane in a film cassette with the protein side facing up. Turn 
off all lights except those appropriate for film (e.g., a red safelight). 
21. Carefully place film on top of the membrane. The recommended exposure time can 
be varied to achieve optimal results (1 second to 5 minutes). Caution: Light emission 
in very intense and any movement between the film and the membrane can cause 
artefacts on the film. 
 
Materials: 
! Electrophoresis Power Supply EPS-301 (Amersham Biosciences) 
! NuPAGE LDS Sample Buffer (Invitrogen, NP0007) 
! NuPAGE Reducing Agent (Invitrogen, NP0004) 
! NuPAGE Tris-Acetate SDS Running Buffer (20X) (Invitrogen, LA0041) 
! NuPAGE MES SDS Running Buffer (20X)(Invitrogen, NP0002) 
! NuPAGE 8-10% Tris-Acetate Gels (Invitrogen) 
! NuPAGE 10% Bis-Tris Gels (, Invitrogen) 
! NuPAGE Transfer Buffer (Invitrogen, NP0006-1) 
! Precision Plus Protein All Blue Standards (Bio-Rad, 161-0373) 
! XCell SureLock Mini-Cell (Novex, E19001) 
! XCellII Blot Module (Novex, E19051) 
! 96% Ethanol () 
! Hybond ECL membrane (Amersham Biosciences, RPN78D) 
! Hyperfilm ELC (Amersham Biosciences, RPN1675K) 
! Drymilk (Irma, supermarket) 
! Streptavidin-HRP (GE Healthcare, RPN1231V) 
! Primary antibody: 
o Ficolin-1: Anti-Human M-ficolin (Hycult biotechnology HP9039) 
o Ficolin-2: Anti-hFicolin-2 (R&D systems, BAF2428) 
o Ficolin-3: Anti-hFicolin-3 (R&D systems, BAF2367) 
! Secondary antibody 
o Anti-rabbit IgG, Horseradish Peroxidase linked F(ab)2 fragment from donkey (GE 
Healthcare, NA9340V) 
o Streptavidin-HRP (GE Healthcare, RPN1231V) 
! SuperSignal West Femto Maximun Sensitivity Substrate (Pierce, 34095) 
! Tween (20X) (Merck, S4321284) 
! PBS (20X) (Bie&Berntsen, Lab7963.1000) 
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Protocol 11: Complement activation assay 
This assay is designed to measure complement activation by detecting neoantigens 
generated on C4b under cleaves of C4. 
 
All additions to the individual wells were 100 !l unless otherwise stated. 
1. Coat the microtiter plate with acetylated BSA or BSA (both 5µg/ml) in carbonate 
buffer. Incubate overnight at 4°C.  
2. Wash 3x in barbital-buffer containing 0.05% Tween-20 (barbital-T) 
3. Block the plate for 1h with barbital-T.  
4. Dilute serum samples in barbital-T. Incubate 30 min at 37°C.  
5. Wash 3x in barbital-T 
6. Add anti-C4c [0.13!g/ml]. Incubate 2h at room temperature, shaking.  
7. Wash 3x in barbital-T 
8. Incubate HRP-conjugated anti-rabbit (1:2000) diluted in barbital-T for 1h at room 
temperature, shaking.  
9. Wash 3x in barbital-T 
10. Develop the microtiter plate for 10-15 min with OPD substrate containing H2O2.  
11. Stop the enzymatic reactions with 50 µl sulphuric acid (1 mol/l).  
12. Measured the optical density at 490nm. 
 
Materials: 
! Microtiter plates (Maxisorb Nunc, 439454) 
! Carbonate buffer (35mM NaHCO3, 
15mMNa2CO3, pH = 9,6) 
! Barbital-buffer (pH 7,4) 
! Tween (VWR, 15797-1)  
! anti-C4c (Dako, Q0369) 
! HRP-conjugated anti-rabbit (GE Healthcare, 
NA934OV) 
! OPD substrate (DAKO, S2045) 
! ELISA reader (Bio-Tek, EL808) 
 
Protocol 12: Total complement system Screen 
This assay is designed for testing deficiencies in the classical, the MBL or the alternative 
pathway. Note, this assay do not screen for deficiencies in the ficolins.  
 
All additions to the individual wells were 100 !l unless otherwise stated. 
1. Start diluting the serum samples as follows: 
! Classical pathway:  1:101 with Diluent CP 
! MBL pathway:  1:101 with Diluent MP. Must stand at room        
temperature for >15 minutes before analysis but less than 60 minutes. 
! Alternative pathway:  1:18 with Diluent AP 
2. In duplicate add Diluent (blank), positive control, negative control and diluted 
samples for each pathway. Incubate 70 minutes at 37°C with lid. 
3. Wash 3 times with 300µl/well of washing solution 
4. Add conjugate and incubate for 30 minutes at room temperature 
5. Wash 3 times as in point 3 
6. Add substrate solution and incubate for 30 minutes at room temperature 
7. Measured the optical density at 490nm. 
 
Materials: 
! Wieslab, Total Complement screen (Euro-diagnostica, Compl 300) 
! ELISA reader (Bio-Tek, EL808) 
 105 
Protocol 13: Quantification of the ficolins by ELISA 
 
This assay is designed to measure the concentration of Ficolin-1, Ficolin-2 or Ficolin-3 in 
different specimens e.g. serum or cell supernatant.  
 
All additions to the individual wells were 100 !l unless otherwise stated. 
1. Coat the microtiter plate with FCN115-V2 [2!g/ml], FCN216 [1!g/ml] or F334 
[0.2!g/ml] for Ficolin-1, Ficolin-2 and Ficolin-3, respectively. Dilute FCN115-
V2 in carbonate butter and dilute FCN216 and FCN334 in 1xPBS and incubate 
overnight at 4°C. 
2. Wash 3x in PBS containing 0,05% Tween (PBS-T) and block the plate with 300µl 
PBS-T for 1 hour at room temperature. 
3. Meanwhile prepare a standard curve for Ficolin-1 using recombinant Ficolin-1 
[0.125!g/ml] or prepare a standard curve using a normal human serum pool for 
Ficolin-2 [1!g/ml] or Ficolin-3 [0.25!g/ml]all diluted in PBS-T and make a two-
fold titration curve.  
4. Add the sample in triplicate diluted in PBS-T. Incubate 3 hours at 37°C. 
5. Wash 3x in PBS-T 
6. Add detection antibodies M-ficolin [0.25!g/ml], FCN219-Biotin [0.2!g/ml] or 
FCN334-Biotin [0.1!g/ml] diluted in PBS-T for Ficolin-1, Ficolin-2 and Ficolin-
3, respectively. Incubate overnight at 4°C. 
7. Wash 3x in PBS-T 
8. Add secondary antibodies anti-rabbit-HRP (1:2.000) for Ficolin-1 or streptavidin-
HRP (1:4.000) for Ficolin-2 and Ficolin-3, respectively. 
9. Wash 3x in PBS-T 
10. Develop the microtiter plate with OPD substrate containing H2O2. 
11. Stop the enzymatic reactions with 50!l/well sulphuric acid [5mmol/l]. 
12. Measure the optical density at 490nm 
 
Materials: 
! Microtiter plate (Maxisorb Nunc, 439454) 
! 1xPBS (Bie&Berntsen, LAB79360) 
! Tween-20 (VWR, 15797-1) 
! Anti-Human M-Ficolin (Hycult biotechnology, HP9039) 
! Anti-rabbit IgG, Horseradish peroxidase (GE Healthcare, NA9340V) 
! Streptavidin-HRP (GE Healthcare, RPN1231V) 
! OPD substrate (DAKO, S2045) 
! ELISA reader (Bio-Tek, EL808) 
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Protocol 14: Ficolin-3 ligand binding 
This assay is designed to measure Ficolin-3 binding to acetylated BSA – an indirect 
method to measure the activation of the lectin pathway by Ficolin-3. 
 
All additions to the individual wells were 100 !l unless otherwise stated. 
13. Coat the microtiter plate with acetylated BSA or BSA (both 5µl/ml) in carbonate 
buffer. Incubate overnight at 4°C.  
14. Wash 3x in barbital-buffer containing 0.05% Tween-20 (barbital-T) 
15. Block the plate for 1h with barbital-T.  
16. Make a two-fold dilution of the samples in barbital-T. Incubate 3h at RT, shaking.  
17. Wash 3x in barbital-T 
18. Add FCN334-Biotin [0.5!g/ml] diluted in PBS-T. Incubate ON at 4°C. 
19. Wash 3x in barbital-T 
20. Incubate streptavidin-HRP (1:4.000) in barbital-T for 1h at room at 37°C. 
21. Wash 3x in barbital-T 
22. Develop the microtiter plate for 10-15 min with OPD substrate containing H2O2.  
23. Stop the enzymatic reactions with 50 µl sulphuric acid (1 mol/l).  
24. Measured the optical density at 490nm. 
 
Materials: 
! Microtiter plates (Maxisorb Nunc, 439454) 
! Carbonate buffer (35mM NaHCO3, 15mMNa2CO3, pH = 9,6) 
! Barbital-buffer (pH 7,4) 
! Tween-20 (VWR, 15797-1)  
! Streptavidin-HRP (GE Healthcare, RPN1231V) 
! OPD substrate (DAKO, S2045) 
! ELISA reader (Bio-Tek, EL808) 
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9.4 Abstract: Characterization of the ficolin genes (FCNs) in 
primates 
 
From the CHD conference 2009, Visegrad, Hungary. 
 
 
Janna Nissen, Tina Hummelshøj, Claus Koch, Peter Garred, Laboratory of Molecular 
Medicine, Department of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark 
 
Ficolins are pattern recognition molecules of importance for innate immunity which key 
function is to recognize carbohydrates such as N-acetylglucosamine and acetylated 
compounds on pathogens and dying host cells. This enables activation of the lectin 
complement pathway by serine proteases and enhancement of phagocytosis.  
 
In human three ficolin genes have been identified: FCN1, FCN2 and FCN3. FCN1 and 
FCN2 are assigned to chromosome 9q34, whereas FCN3 is assigned to chromosome 
1p36.11. The genes encode for the proteins Ficolin-1, Ficolin-2 and Ficolin-3, 
respectively.  
  
In mice two ficolins designated fcn-a and fcn-b and a pseudogene designated fcn-c have 
been identified. FCN1, FCN2, fcn-a and fcn-b are closely related, whereas fcn-c 
corresponds to FCN3. However, no information exists about the FCN genes in primates 
except for the human situation. Until now a functional FCN3 gene has only been 
identified in humans. Thus we wanted to identify and characterize FCN1, FCN2 and 
FCN3 in the primates.  
 
We obtained samples from following primate species: Gorilla, Chimpanzee, Orangutan, 
Baboon, Rhesus macaque, Cynomolgus macaque, Common marmoset, Cotton top 
tamarin, Golden headed lion tamarin, Black lion tamarin and Owl monkey. The results 
were obtained by amplifying the coding sequence of the genes by PCR followed by direct 
sequencing of the PCR product.  
 
The exon organisation was very similar between all primates and humans. Several novel 
inter-individual variations were found in all three FCN genes within each species. 
Interestingly, in FCN1 a G to A polymorphism in position +3458 (Arg93Gln) described 
in humans was also found in the chimpanzees.  
 
These results indicate that all investigated primate species have functional FCN1, FCN2 
and FCN3 genes that are closely related to the human FCN1, FCN2 and FCN3, 
respectively. Moreover, a polymorphism in the FCN1 gene was present in both humans 
and chimpanzees and may thus have an ancient origin.  
 
 
 
 
 108 
9.5 FYF poster presentation, May 2010 
 
 
